[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 38000
1. Vieth M, Stolte M: Elevated risk for gastric adenocarcinoma can be predicted from histomorphology. World J Gastroenterol; 2006 Oct 14;12(38):6109-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated risk for gastric adenocarcinoma can be predicted from histomorphology.
  • In the literature a multistep model from chronic active H pylori-infection through multifocal atrophy, intestinal metaplasia, dysplasia (intraepithelial neoplasia) and carcinoma has been described.
  • This is valid both for first-degree relatives of gastric cancer patients and for patients with gastric adenoma and hyperplastic polyps.
  • In conclusion, corpus-dominant H pylori gastritis is significantly more common in patients with advanced and early gastric cancer, first-degree relatives of patients with gastric cancer, patients with gastric adenoma and gastric hyperplastic polyps.
  • [MeSH-major] Adenocarcinoma / etiology. Gastritis / pathology. Stomach / pathology. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2001 Apr;7(2):243-7 [11819768.001]
  • [Cites] Tumour Biol. 1997;18(5):311-20 [9276031.001]
  • [Cites] Am J Gastroenterol. 1997 Dec;92(12):2220-4 [9399757.001]
  • [Cites] Virchows Arch. 1998 Apr;432(4):311-4 [9565339.001]
  • [Cites] Br J Cancer. 1998 Jul;78(2):263-6 [9683304.001]
  • [Cites] Aliment Pharmacol Ther. 1998 Aug;12(8):735-40 [9726386.001]
  • [Cites] J Gastroenterol Hepatol. 1998 Oct;13(10):1050-7 [9835323.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1999 Jul;11(7):717-20 [10445789.001]
  • [Cites] Cancer. 1958 Nov-Dec;11(6):1149-55 [13608416.001]
  • [Cites] World J Gastroenterol. 2005 Feb 14;11(6):791-6 [15682469.001]
  • [Cites] World J Gastroenterol. 2005 Feb 21;11(7):976-81 [15742399.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Dec;19(6):857-69 [16338646.001]
  • [Cites] Gut. 2000 May;46(5):639-44 [10764706.001]
  • [Cites] Gastroenterol Clin North Am. 2000 Dec;29(4):819-27 [11190066.001]
  • [Cites] Virchows Arch. 2000 Dec;437(6):581-90 [11193468.001]
  • [Cites] Digestion. 2001;64(1):30-9 [11549834.001]
  • [Cites] World J Gastroenterol. 2001 Apr;7(2):248-53 [11819769.001]
  • [Cites] Dig Dis Sci. 2002 Jun;47(6):1248-56 [12064799.001]
  • [Cites] J Clin Pathol. 2002 Oct;55(10):770-3 [12354805.001]
  • [Cites] Helicobacter. 2003 Feb;8(1):29-35 [12603614.001]
  • [Cites] Virchows Arch. 2003 Apr;442(4):317-21 [12715167.001]
  • [Cites] JAMA. 2004 Jan 14;291(2):187-94 [14722144.001]
  • [Cites] J Gastroenterol. 2004;39(4):324-8 [15168242.001]
  • [Cites] Eur J Cancer Prev. 2004 Oct;13(5):457-9 [15452460.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Nov;16(11):1183-8 [15489580.001]
  • [Cites] Endoscopy. 1983 Jan;15(1):8-11 [6822229.001]
  • [Cites] Cancer. 1986 Apr 15;57(8):1528-34 [2418943.001]
  • [Cites] Cancer Res. 1988 Jul 1;48(13):3554-60 [3288329.001]
  • [Cites] J Clin Pathol. 1989 Aug;42(8):834-9 [2768523.001]
  • [Cites] Z Gastroenterol. 1990 May;28(5):229-33 [2402931.001]
  • [Cites] Cancer. 1990 Nov 1;66(9):2047-51 [2224804.001]
  • [Cites] Cancer Causes Control. 1991 Jul;2(4):227-33 [1873452.001]
  • [Cites] Gut. 1992 Apr;33(4):429-31 [1582581.001]
  • [Cites] Cancer. 1992 Jul 1;70(1):50-5 [1606546.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;420(6):489-98 [1609509.001]
  • [Cites] Cancer. 1992 Sep 15;70(6 Suppl):1727-31 [1516027.001]
  • [Cites] Cancer. 1993 Sep 15;72(6):1841-5 [8364862.001]
  • [Cites] Zentralbl Bakteriol. 1993 Sep;280(1-2):137-43 [8280935.001]
  • [Cites] Scand J Gastroenterol Suppl. 1994;201:28-34 [8047821.001]
  • [Cites] Virchows Arch. 1994;425(4):339-47 [7820298.001]
  • [Cites] Gut. 1995 Jan;36(1):12-6 [7890214.001]
  • [Cites] Z Gastroenterol. 1995 Feb;33(2):89-93 [7725762.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1995 May;7(5):461-5 [7614109.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1161-81 [8827022.001]
  • [Cites] Virchows Arch. 1997 Jul;431(1):11-5 [9247628.001]
  • (PMID = 17036380.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 47
  • [Other-IDs] NLM/ PMC4088102
  •  go-up   go-down


2. Hong L, Zhao Y, Wang J, Han Y, Guo W, Jin H, Zhai H, Bai F, Zhang X, Qiao T, Chen Z, Fan D: Reversal of multidrug resistance of adriamycin-resistant gastric adenocarcinoma cells through the up-regulation of DARPP-32. Dig Dis Sci; 2008 Jan;53(1):101-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reversal of multidrug resistance of adriamycin-resistant gastric adenocarcinoma cells through the up-regulation of DARPP-32.
  • The up-regulation of DARPP-32 was found to significantly enhance the sensitivity of cells of human adriamycin (ADR)-resistant gastric adenocarcinoma cell line SGC7901/ADR to vincristine, ADR, 5-fludrouracil and cisplatin.
  • [MeSH-major] Adenocarcinoma / genetics. Antineoplastic Agents / therapeutic use. Dopamine and cAMP-Regulated Phosphoprotein 32 / genetics. Drug Resistance, Multiple / genetics. RNA, Neoplasm / genetics. Stomach Neoplasms / genetics. Up-Regulation

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2001 Nov 2;294(5544):1024-30 [11691979.001]
  • [Cites] Cancer Biol Ther. 2004 Apr;3(4):377-81 [14726695.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6583-92 [16061638.001]
  • [Cites] Int J Cancer. 2005 Jan 10;113(2):213-20 [15386405.001]
  • [Cites] Br J Biomed Sci. 2004;61(4):206-10 [15649014.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Aug 27;321(3):611-6 [15358150.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Mar;20(3):360-5 [15740477.001]
  • [Cites] FEBS Lett. 2001 Aug 17;503(2-3):179-84 [11513878.001]
  • [Cites] Cancer Biol Ther. 2005 Jan;4(1):60-4 [15662122.001]
  • [Cites] Int J Clin Pract. 2005 Jan;59(1):58-61 [15707466.001]
  • [Cites] Br J Cancer. 2004 Jul 5;91(1):119-23 [15188007.001]
  • [Cites] Cancer Res. 1990 Oct 15;50(20):6449-54 [2208103.001]
  • [Cites] Cell Mol Life Sci. 2001 Jun;58(7):931-59 [11497241.001]
  • [Cites] Biochem Cell Biol. 2006 Apr;84(2):199-206 [16609701.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2004 Aug;33(4):350-3 [15363322.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):613-21 [15695406.001]
  • [Cites] Cancer Lett. 2002 Nov 28;185(2):211-8 [12169395.001]
  • [Cites] J Biol Chem. 2005 Mar 4;280(9):7634-44 [15611081.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1547-51 [14508844.001]
  • [Cites] Urol Res. 2000 Apr;28(2):86-92 [10850629.001]
  • [Cites] Hybrid Hybridomics. 2004 Feb;23(1):65-8 [15000850.001]
  • [Cites] Oncogene. 2005 Apr 7;24(15):2474-82 [15735703.001]
  • [Cites] J Physiol Biochem. 2000 Dec;56(4):307-12 [11321524.001]
  • [Cites] Mol Cancer Ther. 2005 Dec;4(12):1936-42 [16373708.001]
  • (PMID = 17492506.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Dopamine and cAMP-Regulated Phosphoprotein 32; 0 / PPP1R1B protein, human; 0 / RNA, Neoplasm; 0 / ZNRD1 protein, human
  •  go-up   go-down


3. Hajsalah M, Fajraoui N, Bouhaouala MH, Mourali S, Ben Mefteh R, Ghrissi A, Ben Hamida K, Ben Romdhane K, Charfi MR: [Soft tissue metastasis revealing an asymptomatic bronchial adenocarcinoma]. Rev Pneumol Clin; 2007 Apr;63(2):111-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Soft tissue metastasis revealing an asymptomatic bronchial adenocarcinoma].
  • We report a case of lung adenocarcinoma disclosed by metastatic dissemination to a forearm muscle.
  • An excisional biopsy of the right forearm showed an infiltration of the muscle with metastatic adenocarcinoma.
  • Bronchoscopy revealed an endobronchial mass that was confirmed by biopsy to be an adenocarcinoma.
  • After eighteen months, the disease progressed but without local muscular recurrence.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Bronchial Neoplasms / diagnosis. Bronchial Neoplasms / pathology. Soft Tissue Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17607217.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


Advertisement
4. Falk S, Anthoney A, Eatock M, Van Cutsem E, Chick J, Glen H, Valle JW, Drolet DW, Albert D, Ferry D, Ajani J: Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma. Br J Cancer; 2006 Aug 21;95(4):450-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma.
  • A two-stage Simon design was used to evaluate the response rate of OSI-7904L, a liposome encapsulated thymidylate synthase inhibitor, in advanced gastric and/or gastroesophageal adenocarcinoma (A-G/GEJA), administered intravenously at 12 mg m(-2) over 30 min every 21 days.
  • Twenty-one patients (42%) had stable disease.
  • [MeSH-minor] Adenocarcinoma. Adult. Aged. Aged, 80 and over. Antineoplastic Agents. Female. Humans. Isoindoles. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1901-11 [11448903.001]
  • [Cites] Int J Oncol. 2000 Oct;17(4):653-8 [10995874.001]
  • [Cites] Int J Colorectal Dis. 2002 Jan;17(1):46-9 [12018454.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 4:13-22 [12401661.001]
  • [Cites] Mol Cancer Ther. 2002 May;1(7):545-52 [12479273.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):815-9 [12610179.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):6004-7 [14522928.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Jun;309(3):894-902 [14982966.001]
  • [Cites] Methods Mol Biol. 2004;281:91-103 [15220523.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Clin Chem. 1993 Feb;39(2):263-71 [8432015.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1407-12 [7882343.001]
  • [Cites] Cell Struct Funct. 1995 Jun;20(3):191-7 [7586009.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):176-82 [8558194.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):261-7 [8996151.001]
  • [Cites] Ann Oncol. 1997 Feb;8(2):163-8 [9093725.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5487-95 [16061865.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6957-65 [16145066.001]
  • [Cites] Br J Cancer. 2006 Jan 30;94(2):203-7 [16333305.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2898-904 [12782596.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12810-5 [10536004.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2648-57 [10894863.001]
  • [Cites] J Exp Clin Cancer Res. 2000 Jun;19(2):189-95 [10965817.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):1996-2004 [11956258.001]
  • (PMID = 16880795.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ((S)-2-(5-(1,2-dihydro-3-methyl-1-oxobenzo(f)-quinazoline-9-yl)methyl)amino-1-oxo-2-isoindolynyl)-glutaric acid; 0 / Antineoplastic Agents; 0 / Glutarates; 0 / Isoindoles; 0 / Quinazolines
  • [Other-IDs] NLM/ PMC2360664
  •  go-up   go-down


5. Candioli S, Manigrasso A, Arcieri S, Caruso F, Tarroni D, Mascagni D, Palazzini G, Filippini A: [Adenocarcinoma following restorative proctocolectomy for ulcerative colitis: a case report and review of the literature]. G Chir; 2007 Oct;28(10):371-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenocarcinoma following restorative proctocolectomy for ulcerative colitis: a case report and review of the literature].
  • [Transliterated title] Adenocarcinoma insorto dopo proctocolectomia restaurativa per rettocolite ulcerosa: presentazione di un caso clinico e revisione della letteratura.
  • The occurrence of adenocarcinoma arising near or into the ileal pouch is rare.
  • The authors report a case of a 67-year old male who developed an adenocarcinoma in the small rectal stump 12 years after a restorative proctocolectomy with double stapled ileal pouch-low rectal anastomosis for ulcerative colitis unresponsive to medical treatment.
  • [MeSH-major] Adenocarcinoma / etiology. Colitis, Ulcerative / complications. Colitis, Ulcerative / surgery. Colonic Pouches. Proctitis / surgery. Proctocolectomy, Restorative. Rectal Neoplasms / etiology. Rectum / surgery

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17915051.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 43
  •  go-up   go-down


6. Wilkinson N, Scott-Conner CE: Surgical therapy for colorectal adenocarcinoma. Gastroenterol Clin North Am; 2008 Mar;37(1):253-67, ix
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical therapy for colorectal adenocarcinoma.
  • Unfortunately, advanced disease at diagnosis is still all too common.
  • Locally advanced rectal cancer, node-positive colon cancer, and metastatic disease still compose a significant proportion of colon and rectal cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colorectal Neoplasms / surgery. Laparoscopy / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18313549.001).
  • [ISSN] 0889-8553
  • [Journal-full-title] Gastroenterology clinics of North America
  • [ISO-abbreviation] Gastroenterol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


7. Park JK, Hong R, Kim KJ, Lee TB, Lim SC: Significance of p-STAT3 expression in human colorectal adenocarcinoma. Oncol Rep; 2008 Sep;20(3):597-604
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of p-STAT3 expression in human colorectal adenocarcinoma.
  • To examine the relationship between p-STAT3 and the clinicopathological parameters of colorectal adenocarcinoma (CRA), we initially conducted immunohistochemical (IHC) analyses on formalin-fixed tissues.
  • A total of 127 invasive CRA, 20 colorectal adenomas and 20 normal mucosae were obtained.
  • The statistically significant difference of immunoreactivity for p-STAT3 between the CRA and adenoma, and between the CRA and normal mucosae was identified.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Carcinoma in Situ / genetics. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Colon / metabolism. Colon / pathology. Humans. Immunoenzyme Techniques. Neoplasm Invasiveness. Neoplasm Staging. Phosphorylation. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18695911.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human
  •  go-up   go-down


8. Chen L, Tian G, Shao C, Cobos E, Gao W: Curcumin modulates eukaryotic initiation factors in human lung adenocarcinoma epithelial cells. Mol Biol Rep; 2010 Oct;37(7):3105-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curcumin modulates eukaryotic initiation factors in human lung adenocarcinoma epithelial cells.
  • The objective of this study was to exam the curcumin cytotoxic effect and modulation of two major rate-limiting translation initiation factors, including eIF2α and eIF4E protein expression levels in lung adenocarcinoma epithelial cell line A549.
  • [MeSH-major] Adenocarcinoma / metabolism. Curcumin / pharmacology. Epithelial Cells / drug effects. Epithelial Cells / metabolism. Eukaryotic Initiation Factors / metabolism. Lung Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CURCUMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6B):4423-30 [17201164.001]
  • [Cites] Cancer Lett. 2004 May 28;208(2):163-70 [15142674.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):10943-51 [11278364.001]
  • [Cites] Oncogene. 1997 Jul 31;15(5):579-84 [9247311.001]
  • [Cites] Endocrinology. 2008 Aug;149(8):4158-67 [18450960.001]
  • [Cites] EMBO J. 1995 Aug 1;14(15):3828-34 [7641700.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2164-71 [11596034.001]
  • [Cites] Zhong Yao Cai. 2004 Dec;27(12):923-7 [15807244.001]
  • [Cites] J Neurochem. 2007 Nov;103(4):1368-80 [17760864.001]
  • [Cites] Eur J Biochem. 2002 Nov;269(22):5350-9 [12423333.001]
  • [Cites] Bioessays. 1996 Mar;18(3):243-50 [8867739.001]
  • [Cites] Biochem J. 1999 Sep 15;342 Pt 3:519-26 [10477262.001]
  • [Cites] Clin Biochem. 2006 Apr;39(4):404-9 [16375881.001]
  • [Cites] J Biol Chem. 2006 Sep 8;281(36):26633-44 [16835242.001]
  • [Cites] Biochem Pharmacol. 2008 Dec 1;76(11):1340-51 [18755156.001]
  • [Cites] Cancer Res. 2009 Feb 1;69(3):1000-8 [19176385.001]
  • [Cites] Adv Exp Med Biol. 2007;595:227-43 [17569214.001]
  • [Cites] Arch Biochem Biophys. 2006 Aug 15;452(2):138-48 [16843428.001]
  • [Cites] Planta Med. 2007 Sep;73(11):1176-81 [17823871.001]
  • [Cites] Clin Lung Cancer. 2005 Sep;7 Suppl 1:S13-8 [16159415.001]
  • [Cites] J Biol Chem. 2005 Apr 8;280(14 ):14189-202 [15684420.001]
  • [Cites] J Biol Chem. 2002 May 24;277(21):19198-205 [11877448.001]
  • [Cites] J Neurochem. 2001 Aug;78(4):779-87 [11520898.001]
  • [Cites] Biochem Pharmacol. 2008 Dec 1;76(11):1590-611 [18775680.001]
  • [Cites] Biochem J. 2003 Jan 15;369(Pt 2):213-25 [12215171.001]
  • [Cites] Trends Biochem Sci. 1997 Sep;22(9):345-9 [9301335.001]
  • [Cites] Cancer Lett. 2008 Oct 8;269(2):199-225 [18479807.001]
  • [Cites] Anticancer Res. 2001 Mar-Apr;21(2A):873-8 [11396178.001]
  • [Cites] Hum Pathol. 2008 Jun;39(6):910-6 [18234281.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):757-64 [16550606.001]
  • [Cites] Gene Expr. 1997;6(6):349-60 [9495316.001]
  • [Cites] J Zhejiang Univ Sci B. 2009 Feb;10(2):93-102 [19235267.001]
  • [Cites] Cell Prolif. 2009 Apr;42(2):195-206 [19236381.001]
  • [Cites] Cancer Lett. 2008 Dec 8;272(1):77-90 [18701210.001]
  • [Cites] Annu Rev Biochem. 1999;68:913-63 [10872469.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Feb 23;353(4):1040-5 [17198682.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Feb 29;367(1):54-9 [18164262.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):1080-8 [12942578.001]
  • [Cites] Annu Rev Biochem. 1991;60:717-55 [1883206.001]
  • [Cites] Cancer Res. 2008 Sep 15;68(18):7428-38 [18794131.001]
  • [Cites] Mol Pharmacol. 2004 Jan;65(1):99-110 [14722241.001]
  • [Cites] Cancer Lett. 1996 Apr 19;102(1-2):113-23 [8603359.001]
  • [Cites] J Med Chem. 2009 Jan 22;52(2):484-91 [19113979.001]
  • [Cites] Oncogene. 1999 Apr 15;18(15):2507-17 [10229202.001]
  • [Cites] Mol Cell Biol. 2004 Mar;24(5):2025-40 [14966282.001]
  • (PMID = 19826913.001).
  • [ISSN] 1573-4978
  • [Journal-full-title] Molecular biology reports
  • [ISO-abbreviation] Mol. Biol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / EIF4EBP1 protein, human; 0 / Eukaryotic Initiation Factor-2; 0 / Eukaryotic Initiation Factor-4E; 0 / Eukaryotic Initiation Factors; 0 / Phosphoproteins; IT942ZTH98 / Curcumin
  •  go-up   go-down


9. Liu K, Jiang L, Zhou X: Association of p73 G4C14-to-A4T14 polymorphism at exon 2 with the response of human lung adenocarcinoma cell lines to chemotherapy. Cell Biol Int; 2010 Feb;34(2):185-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of p73 G4C14-to-A4T14 polymorphism at exon 2 with the response of human lung adenocarcinoma cell lines to chemotherapy.
  • In order to assess the effect of p73 gene polymorphism G4C14-A4T14 on cisplatin-based chemosensitivity of human lung adenocarcinoma cell lines, we examined the differences in biological character and drug sensitivity affected by cisplatin between human lung adenocarcinoma cell lines A549 and P15.
  • Our data in vitro suggest that p73 G4C14-A4T14 polymorphism has no significant relationship to the cisplatin-based chemosensitivity in human lung adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19947923.001).
  • [ISSN] 1095-8355
  • [Journal-full-title] Cell biology international
  • [ISO-abbreviation] Cell Biol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Di Martino N, Izzo G, Cosenza A, Cerullo G, Torelli F, Brillantino A, del Genio A: Adenocarcinoma of gastric cardia in the elderly: surgical problems and prognostic factors. World J Gastroenterol; 2005 Sep 7;11(33):5123-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of gastric cardia in the elderly: surgical problems and prognostic factors.
  • AIM: To analyze retrospectively, our results about patients who underwent surgical treatment for adenocarcinoma of the cardia in relation to age, in order to evaluate surgical problems and prognostic factors.
  • METHODS: From January 1987 to March 2003, 140 patients with adenocarcinoma of the cardia underwent resection in the authors institution.
  • [MeSH-major] Adenocarcinoma / surgery. Aged. Cardia. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16127740.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4320383
  •  go-up   go-down


11. Chen T, Wu F, Chen FM, Tian J, Qu S: Variations of very low-density lipoprotein receptor subtype expression in gastrointestinal adenocarcinoma cells with various differentiations. World J Gastroenterol; 2005 May 14;11(18):2817-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variations of very low-density lipoprotein receptor subtype expression in gastrointestinal adenocarcinoma cells with various differentiations.
  • AIM: This study is aimed at investigating the expression and possible significances of very low-density lipoprotein receptor (VLDLR) subtypes in gastroenteric adenocarcinoma tissues and cells with various differentiations.
  • METHODS: Thirty-one cases of gastroenteric carcinoma/adjacent normal tissues were enrolled in the study, which were diagnosed and classified by the clinicopathological diagnosis.
  • The expression of VLDLR subtypes was detected in gastroenteric carcinoma/adjacent normal tissues and three various differentiated human gastric adenocarcinoma cell lines (MKN28, SGC7901 and MKN45) by reverse transcription polymerase chain reaction (RT-PCR) and Western blot analysis.
  • RESULTS: Two VLDLR subtypes, namely, type II VLDLR and type I VLDLR, were found to express changes in gastroenteric carcinoma tissues, their adjacent normal tissue, and gastric adenocarcinoma cell lines as well.
  • Type II VLDLR is predominantly expressed in poorly- or moderately-differentiated gastroenteric carcinoma tissues and gastric adenocarcinoma cell lines, whereas type I VLDLR is mainly detected in well-differentiated intestinal carcinoma tissues and gastric adenocarcinoma cells compared with the adjacent normal tissues.
  • CONCLUSION: The results suggested that the variations of the VLDLR subtype expression might be correlated with the progress and differentiation of gastroenteric carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Gastrointestinal Neoplasms / metabolism. Receptors, LDL / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15884130.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / Receptors, LDL; 0 / VLDL receptor
  • [Other-IDs] NLM/ PMC4305924
  •  go-up   go-down


12. Kobayashi N, Toyooka S, Ichimura K, Soh J, Yamamoto H, Matsuo K, Otani H, Jida M, Kubo T, Tsukuda K, Kiura K, Sano Y, Date H: Non-BAC component but not epidermal growth factor receptor gene mutation is associated with poor outcomes in small adenocarcinoma of the lung. J Thorac Oncol; 2008 Jul;3(7):704-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-BAC component but not epidermal growth factor receptor gene mutation is associated with poor outcomes in small adenocarcinoma of the lung.
  • OBJECTIVE: The purpose of this study was to identify risk factors for poor clinical outcome after surgical resection of small lung adenocarcinoma.
  • MATERIALS AND METHODS: Clinical records of 127 patients who had pathologic stage IA lung adenocarcinoma 20 mm or less and who had undergone a lobectomy with mediastinal lymph node dissection were reviewed.
  • RESULTS: Based on the percentage of non-BAC component, 127 patients were classified as follows: 26 in group I, BAC, 46 in group II mixed subtype with >or= 50% BAC, 18 in group III, mixed subtype with under 50% BAC, and 37 in group IV, mixed subtype with all non-BAC components or a pure pattern of one of the non-BAC components.
  • They were also independent risk factors for poor disease-free survival (p = 0.025 and p = 0.027, respectively).
  • CONCLUSION: The high non-BAC component but not EGFR mutation status, is an independent risk factor for both recurrence and poor prognosis in patients with stage IA lung adenocarcinoma <or=20 mm.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Carcinoma, Non-Small-Cell Lung / pathology. Genes, erbB-1 / genetics. Lung Neoplasms / pathology. Mutation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Risk Factors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18594314.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Iguchi Y, Mano K, Goto Y, Nakano T, Nomura F, Shimokata T, Iwamizu-Watanabe S, Hashizume Y: Miliary brain metastases from adenocarcinoma of the lung: MR imaging findings with clinical and post-mortem histopathologic correlation. Neuroradiology; 2007 Jan;49(1):35-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Miliary brain metastases from adenocarcinoma of the lung: MR imaging findings with clinical and post-mortem histopathologic correlation.
  • METHODS: We report a 66-year-old man with miliary brain metastases from adenocarcinoma of the lung, describing MRI and neuropathologic findings in the context of previously reported cases.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / secondary. Brain Neoplasms / pathology. Brain Neoplasms / secondary. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroradiology. 1988;30(3):265-8 [3405417.001]
  • [Cites] Cancer. 1996 Apr 15;77(8):1551-5 [8608542.001]
  • [Cites] AMA Arch Neurol Psychiatry. 1951 Feb;65(2):161-73 [14798993.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):564-6 [9046318.001]
  • [Cites] AJNR Am J Neuroradiol. 1987 May-Jun;8(3):553-4 [3111217.001]
  • [Cites] AJNR Am J Neuroradiol. 1993 May-Jun;14 (3):540-2 [8517338.001]
  • [Cites] J Clin Oncol. 2001 Dec 1;19(23 ):4340-1 [11731517.001]
  • [Cites] Adv Neurol. 1978;19:579-92 [570349.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1993 Jan;56(1):110-1 [8429312.001]
  • [Cites] Neuropathology. 2005 Jun;25(2):153-8 [15875909.001]
  • [Cites] Neuroradiology. 1997 Jun;39(6):437-40 [9225326.001]
  • [Cites] Neurology. 1987 Nov;37(11):1817-8 [3670620.001]
  • [Cites] Neuroradiology. 1989;31(2):200 [2747904.001]
  • (PMID = 17103154.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Malaisrie SC, Hofstetter WL, Correa AM, Ajani JA, Komaki RR, Rice DC, Vaporciyan AA, Walsh GL, Roth JA, Wu TT, Swisher SG: The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer; 2006 Sep 1;107(5):967-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma.
  • BACKGROUND: Tumor viability assessed by pathologic analysis of resected specimens in patients with preoperatively treated esophageal adenocarcinoma (EAC) is a prognostic indicator.
  • Pathologic tumor response, overall survival, and disease-free survival were assessed according to treatment.
  • In the CCRT group, the median disease-free survival was 43 months, and the 3-year disease-free survival rate was 54%; in the CRT group, the median disease-free survival was 18 months, and the 3-year disease-free survival rate was 36% (HR, 0.72; P = .047).
  • Subset analysis of patients with clinical Stage III/IVA disease showed a median overall survival of 51 months with a 3-year overall survival rate of 58% in the CCRT group and a median overall survival of 20 months with a 3-year overall survival rate of 28% in the CRT group (HR, 0.57; P = .019).
  • Overall survival and disease-free survival were increased in patients who received CCRT, especially in the subset of patients who had more advanced disease.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer. 2007 Apr 1;109(7):1448-9; author reply 1449 [17328063.001]
  • (PMID = 16874819.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Yang S, Su J, Cao J, Zhang P, Lu J, Xie W: [Establishment of a Novel Chinese Human Lung Adenocarcinoma Cell Line CPA-Yang1 which Produces Highly Bone Metastases in Immunodeficient Mice.]. Zhongguo Fei Ai Za Zhi; 2009 Jul 20;12(7):753-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Establishment of a Novel Chinese Human Lung Adenocarcinoma Cell Line CPA-Yang1 which Produces Highly Bone Metastases in Immunodeficient Mice.].
  • The aim of this study is to establish a Chinese lung adenocarcinoma cell line with high metastasis potency for exploring the mechanism of occurrence and development in lung cancer.
  • METHODS: The cell came from the pericardial effusion of a fifty-year old male patient with lung adenocarcinoma and the cells in primary culture were obtained successfully.
  • Quantitative real-time PCR was used to examined and compared SPC-A-1 lung adenocarcinoma, VEGF-C, IL-6, IL-8, genes were overexpressed.
  • CONCLUSIONS: Tne novel strain CPA-Yang1 is an parental cell with characteristics of bone metastasis of Chinese lung adenocarcinoma.


16. Goda K, Tajiri H, Ikegami M, Urashima M, Nakayoshi T, Kaise M: Usefulness of magnifying endoscopy with narrow band imaging for the detection of specialized intestinal metaplasia in columnar-lined esophagus and Barrett's adenocarcinoma. Gastrointest Endosc; 2007 Jan;65(1):36-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of magnifying endoscopy with narrow band imaging for the detection of specialized intestinal metaplasia in columnar-lined esophagus and Barrett's adenocarcinoma.
  • OBJECTIVE: To examine the values of fine mucosal patterns and the capillary patterns observed by magnifying endoscopy with narrow band imaging (MENBI) for the detection of SIM in columnar-lined esophagus and superficial Barrett's adenocarcinoma.
  • PATIENTS: Fifty-eight patients, including 4 with superficial Barrett's adenocarcinoma.
  • RESULTS: Upon observation, all 6 adenocarcinoma sites were classified as irregular patterns in both the fine mucosal patterns and capillary patterns.
  • The addition of capillary patterns to fine mucosal patterns appeared to improve the diagnostic value for detecting SIM and superficial Barrett's adenocarcinoma upon observation by MENBI.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / diagnosis. Endoscopy, Gastrointestinal / methods. Esophageal Neoplasms / diagnosis. Esophagus / pathology. Intestinal Mucosa / pathology

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastrointest Endosc. 2007 Jan;65(1):47-9 [17185079.001]
  • (PMID = 17185078.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Kaneko OF, Lee DM, Wong J, Kadell BM, Reber HA, Lu DS, Raman SS: Performance of multidetector computed tomographic angiography in determining surgical resectability of pancreatic head adenocarcinoma. J Comput Assist Tomogr; 2010 Sep-Oct;34(5):732-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Performance of multidetector computed tomographic angiography in determining surgical resectability of pancreatic head adenocarcinoma.
  • OBJECTIVE: To evaluate the performance of multidetector computed tomographic angiography (MDCTA) in assessing the surgical resectability of pancreatic head adenocarcinoma.
  • METHODS: With institutional review board approval, radiographic, surgical, and pathological records of 203 consecutive patients with adenocarcinoma of the pancreatic head were analyzed retrospectively.
  • CONCLUSIONS: Multidetector CT angiography offers accurate and valuable preoperative assessment of surgical resectability of pancreatic ductal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radiography. Pancreatic Neoplasms / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20861777.001).
  • [ISSN] 1532-3145
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 4419T9MX03 / Iohexol
  •  go-up   go-down


18. Lowery MA, O'Reilly EM: Pancreatic adenocarcinoma: new approaches to a challenging malignancy. Oncology (Williston Park); 2010 Dec;24(14):1339, 1342
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic adenocarcinoma: new approaches to a challenging malignancy.
  • [MeSH-major] Adenocarcinoma / therapy. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Oncology (Williston Park). 2010 Dec;24(14):1329-34 [21294478.001]
  • (PMID = 21294480.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  •  go-up   go-down


19. Srilatha PS, Roy A: Villoglandular papillary adenocarcinoma of cervix associated with cervical intraepithelial neoplasia: a case report and review of literature. Indian J Pathol Microbiol; 2007 Oct;50(4):819-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular papillary adenocarcinoma of cervix associated with cervical intraepithelial neoplasia: a case report and review of literature.
  • Well differentiated villoglandular adenocarcinoma of uterine cervix is a rare tumour which usually occurs in young women.
  • Histopathological findings were consistent with villoglandular papillary adenocarcinoma associated with high grade cervical intraepithelial neoplasia (CIN-3).
  • A review of literature showed that only occasional cases showing disease spread have been reported, suggesting caution in the management and regular follow up of the patient.
  • [MeSH-major] Adenocarcinoma, Papillary / complications. Adenocarcinoma, Papillary / pathology. Cervical Intraepithelial Neoplasia / complications. Cervical Intraepithelial Neoplasia / pathology. Uterine Cervical Neoplasms / complications. Uterine Cervical Neoplasms / pathology


20. González CA, Pera G, Agudo A, Bueno-de-Mesquita HB, Ceroti M, Boeing H, Schulz M, Del Giudice G, Plebani M, Carneiro F, Berrino F, Sacerdote C, Tumino R, Panico S, Berglund G, Simán H, Hallmans G, Stenling R, Martinez C, Dorronsoro M, Barricarte A, Navarro C, Quiros JR, Allen N, Key TJ, Bingham S, Day NE, Linseisen J, Nagel G, Overvad K, Jensen MK, Olsen A, Tjønneland A, Büchner FL, Peeters PH, Numans ME, Clavel-Chapelon F, Boutron-Ruault MC, Roukos D, Trichopoulou A, Psaltopoulou T, Lund E, Casagrande C, Slimani N, Jenab M, Riboli E: Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Int J Cancer; 2006 May 15;118(10):2559-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST).
  • No evidence exists from cohort studies about adenocarcinoma of oesophagus (ACO).
  • [MeSH-major] Adenocarcinoma / prevention & control. Esophageal Neoplasms / prevention & control. Fruit. Stomach Neoplasms / prevention & control. Vegetables

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • [CommentIn] Int J Cancer. 2006 Dec 15;119(12):2991; author reply 2992 [17016826.001]
  • (PMID = 16380980.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


21. Khosravi Shahi P, Pérez Manga G: [Gastric adenocarcinoma: new therapeutical options]. An Med Interna; 2007 Mar;24(3):107-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric adenocarcinoma: new therapeutical options].
  • [Transliterated title] Adenocarcinoma gástrico: nuevas opciones terapéuticas.
  • [MeSH-major] Adenocarcinoma / therapy. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17590129.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] Editorial; Review
  • [Publication-country] Spain
  • [Number-of-references] 12
  •  go-up   go-down


22. Kheradmand A, Smith T: Dural metastatic adenocarcinoma mimicking meningioma. Neurology; 2010 Apr 27;74(17):1396
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dural metastatic adenocarcinoma mimicking meningioma.
  • [MeSH-major] Adenocarcinoma / secondary. Dura Mater / pathology. Meningeal Neoplasms / secondary. Meningioma / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Lung Neoplasms / pathology. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20421586.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Szachnowicz S, Cecconello I, Ribeiro U, Iriya K, El Ibrahim R, Takeda FR, Corbett CE, Vaz Safatle-Ribeiro A: Mucin pattern reflects the origin of the adenocarcinoma in Barrett's esophagus: a retrospective clinical and laboratorial study. World J Surg Oncol; 2009;7:27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucin pattern reflects the origin of the adenocarcinoma in Barrett's esophagus: a retrospective clinical and laboratorial study.
  • BACKGROUND: Mucin immunoexpression in adenocarcinoma arising in Barrett's esophagus (BE) may indicate the carcinogenesis pathway.
  • The aim of this study was to evaluate resected specimens of adenocarcinoma in BE for the pattern of mucins and to correlate to the histologic classification.
  • METHODS: Specimens were retrospectively collected from thirteen patients who underwent esophageal resection due to adenocarcinoma in BE.
  • CONCLUSION: Barrett's esophagus adenocarcinoma shows either gastric or intestinal type pattern of mucin expression.
  • The two types of tumors developed in Barrett's esophagus may reflect the original cell type involved in the malignant transformation.
  • [MeSH-major] Adenocarcinoma / etiology. Barrett Esophagus / complications. Esophageal Neoplasms / etiology. Mucin 5AC / analysis. Mucin-2 / analysis

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1999 Dec;35(6):517-24 [10583575.001]
  • [Cites] Clinics (Sao Paulo). 2005 Apr;60(2):103-12 [15880245.001]
  • [Cites] Gut. 2000 Dec;47(6):753-61 [11076872.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):660-8 [12152167.001]
  • [Cites] Gan. 1968 Jun;59(3):251-8 [5726267.001]
  • [Cites] Histochem J. 1981 Nov;13(6):931-9 [7338482.001]
  • [Cites] Hum Pathol. 1983 Jan;14(1):42-61 [6832749.001]
  • [Cites] Am J Clin Pathol. 1984 Apr;81(4):500-3 [6702752.001]
  • [Cites] Am J Surg. 1985 Sep;150(3):365-9 [4037198.001]
  • [Cites] Gut. 1986 Sep;27(9):1062-8 [3758820.001]
  • [Cites] J Biol Chem. 1989 Apr 15;264(11):6480-7 [2703501.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1989;414(4):359-63 [2496524.001]
  • [Cites] Cancer. 1991 Oct 15;68(8):1731-6 [1913516.001]
  • [Cites] Crit Rev Biochem Mol Biol. 1992;27(1-2):57-92 [1727693.001]
  • [Cites] Dig Dis Sci. 1992 Jan;37(1):137-43 [1728519.001]
  • [Cites] Gastroenterol Clin North Am. 1991 Dec;20(4):817-34 [1787015.001]
  • [Cites] Am J Gastroenterol. 1992 Jun;87(6):746-50 [1590313.001]
  • [Cites] Am J Respir Cell Mol Biol. 1992 Dec;7(6):557-64 [1449803.001]
  • [Cites] Cancer Res. 1993 Feb 1;53(3):641-51 [7678777.001]
  • [Cites] J Histochem Cytochem. 1993 Oct;41(10):1479-85 [8245407.001]
  • [Cites] J Biol Chem. 1994 Jan 28;269(4):2440-6 [8300571.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):973-81 [8144002.001]
  • [Cites] Gastroenterology. 1994 Jul;107(1):28-36 [8020672.001]
  • [Cites] Lancet. 1994 Dec 3;344(8936):1533-6 [7983953.001]
  • [Cites] Am J Surg Pathol. 1995 Feb;19(2):183-91 [7832278.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2681-90 [7780985.001]
  • [Cites] Biochem J. 1995 Jul 1;309 ( Pt 1):221-9 [7619060.001]
  • [Cites] Gastroenterology. 1995 Nov;109(5):1541-6 [7557137.001]
  • [Cites] Biochem Soc Trans. 1995 Nov;23(4):795-9 [8654840.001]
  • [Cites] Biochem Soc Trans. 1995 Nov;23(4):840-5 [8654850.001]
  • [Cites] Am J Gastroenterol. 1997 Mar;92(3):414-8 [9068460.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1028-32 [9672324.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1003-7 [10070955.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):965-73 [10233832.001]
  • [Cites] Ann Surg. 2000 Mar;231(3):303-21 [10714623.001]
  • (PMID = 19272137.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-2
  • [Other-IDs] NLM/ PMC2662840
  •  go-up   go-down


24. Montironi R, Ball RY, Griffiths DF, Grigor K, Harnden PM, Jarmulowicz M, McWilliam LJ, Moseley RP, Parkinson MC, Santinelli A, Moss SM, Melia JW: Bayesian belief network for the Gleason patterns in prostatic adenocarcinoma: development of a diagnostic decision support system for educational purposes. Anal Quant Cytol Histol; 2008 Feb;30(1):8-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bayesian belief network for the Gleason patterns in prostatic adenocarcinoma: development of a diagnostic decision support system for educational purposes.
  • OBJECTIVE: To develop a Bayesian belief network (BBN) for Gleason grading of prostate adenocarcinoma.
  • CONCLUSION: The BBN for Gleason grading is readily implemented, allowing use of linguistic variables and descriptive terms and accumulation of evidence presented by morphologic clues.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Decision Support Systems, Clinical. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / pathology
  • [MeSH-minor] Bayes Theorem. Humans. Male. Neoplasm Staging. Observer Variation. Pathology, Clinical / education. Prostate. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18459582.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501019
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. Lequaglie C, Della Morte A, Feudale E, Giudice G: [Solitary metachronous metastasis of the sternum from pancreatic adenocarcinoma]. Chir Ital; 2007 Nov-Dec;59(6):901-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Solitary metachronous metastasis of the sternum from pancreatic adenocarcinoma].
  • [Transliterated title] Metastasi umica metacrona dello sterno da adenocarcinoma del pancreas.
  • Sternal metastases from adenocarcinoma of the pancreas are extremely rare, and even more so when solitary.
  • Two years earlier, the patient reported on here, a 67-year-old man with a solitary osteolytic lesion of the sternal manubrium, had undergone a duodeno-cephalopancreatectomy for adenocarcinoma of the pancreas (G2, pY3, pN1) followed by adjuvant radio-chemotherapy.
  • The histological examination revealed secondary adenocarcinoma with 3 mediastinal metastatic lymph nodes.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Neoplasms / secondary. Bone Neoplasms / surgery. Pancreatic Neoplasms. Sternum

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18361001.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


26. Hartojo W, Silvers AL, Thomas DG, Seder CW, Lin L, Rao H, Wang Z, Greenson JK, Giordano TJ, Orringer MB, Rehemtulla A, Bhojani MS, Beer DG, Chang AC: Curcumin promotes apoptosis, increases chemosensitivity, and inhibits nuclear factor kappaB in esophageal adenocarcinoma. Transl Oncol; 2010 Apr;3(2):99-108
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curcumin promotes apoptosis, increases chemosensitivity, and inhibits nuclear factor kappaB in esophageal adenocarcinoma.
  • We investigated the effects of curcumin on NF-kappaB activity, on cell viability, and as a chemosensitizing agent with 5-fluorouracil (5-FU) or cisplatin (CDDP) in esophageal adenocarcinoma (EAC).

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1991 Jan 1;51(1):365-71 [1703038.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2351-62 [15476283.001]
  • [Cites] Cancer Res. 1993 Sep 1;53(17):3976-85 [8358726.001]
  • [Cites] J Clin Invest. 1996 Nov 1;98(9):2120-8 [8903332.001]
  • [Cites] Mol Cell Biol. 1997 Jul;17(7):3629-39 [9199297.001]
  • [Cites] Cell. 1997 Oct 17;91(2):243-52 [9346241.001]
  • [Cites] Science. 1997 Oct 31;278(5339):860-6 [9346484.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):2952-60 [9399940.001]
  • [Cites] Cancer Res. 1997 Dec 15;57(24):5571-8 [9407969.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Genes Dev. 1999 Feb 15;13(4):382-7 [10049353.001]
  • [Cites] Genes Dev. 1999 Feb 15;13(4):400-11 [10049356.001]
  • [Cites] Oncogene. 1999 Apr 22;18(16):2567-77 [10353600.001]
  • [Cites] J Biol Chem. 1999 Aug 13;274(33):22932-40 [10438458.001]
  • [Cites] J Immunol. 1999 Sep 15;163(6):3474-83 [10477620.001]
  • [Cites] Oncogene. 1999 Oct 28;18(44):6013-20 [10557090.001]
  • [Cites] Anticancer Res. 1999 Sep-Oct;19(5A):3675-80 [10625938.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6847-54 [15501961.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):120-5 [15668484.001]
  • [Cites] Cancer Lett. 2005 Jun 16;224(1):53-65 [15911101.001]
  • [Cites] Am J Gastroenterol. 2005 Jun;100(6):1257-64 [15929754.001]
  • [Cites] Eur J Cancer. 2005 Sep;41(13):1955-68 [16081279.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12507-12 [16109772.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7490-8 [16243823.001]
  • [Cites] Nature. 2006 May 25;441(7092):431-6 [16724054.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2844-50 [17121931.001]
  • [Cites] Neoplasia. 2006 Dec;8(12):1062-71 [17217624.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):1022-30 [17363495.001]
  • [Cites] J Biol Chem. 2007 Jun 1;282(22):16244-55 [17403674.001]
  • [Cites] J Neurochem. 2007 Jul;102(2):522-38 [17596214.001]
  • [Cites] J Surg Res. 2007 Sep;142(1):184-94 [17603079.001]
  • [Cites] Cancer Biol Ther. 2008 Sep;7(9):1407-14 [18719365.001]
  • [Cites] Cancer Res. 2009 Jan 15;69(2):672-7 [19147583.001]
  • [Cites] Br J Cancer. 2009 Nov 3;101(9):1585-95 [19809435.001]
  • [Cites] Oncogene. 2000 Nov 16;19(48):5498-506 [11114727.001]
  • [Cites] Anticancer Res. 2001 Jul-Aug;21(4B):2895-900 [11712783.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Biochem Pharmacol. 2002 Apr 15;63(8):1423-30 [11996883.001]
  • [Cites] Biochem Pharmacol. 2002 May 1;63(9):1709-16 [12007574.001]
  • [Cites] Nat Med. 2002 Aug;8(8):816-24 [12118244.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):6-11 [12517768.001]
  • [Cites] Ann Surg. 2004 Apr;239(4):491-500 [15024310.001]
  • [Cites] Melanoma Res. 2004 Jun;14(3):165-71 [15179184.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):679-92 [15252836.001]
  • [Cites] Genes Dev. 2004 Sep 15;18(18):2195-224 [15371334.001]
  • [Cites] Dig Dis Sci. 2004 Aug;49(7-8):1075-83 [15387324.001]
  • [Cites] J Biol Chem. 1995 Oct 20;270(42):24995-5000 [7559628.001]
  • (PMID = 20360934.001).
  • [ISSN] 1936-5233
  • [Journal-full-title] Translational oncology
  • [ISO-abbreviation] Transl Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA071606; United States / NCI NIH HHS / CA / P30 CA046592; United States / NCI NIH HHS / CA / K08 CA127212-02; United States / NCI NIH HHS / CA / R01 CA129623; United States / NCI NIH HHS / CA / CA127212-02; United States / NCI NIH HHS / CA / K08 CA127212; United States / NCI NIH HHS / CA / T32 CA009672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2847317
  •  go-up   go-down


27. Jatoi A, Murphy BR, Foster NR, Nikcevich DA, Alberts SR, Knost JA, Fitch TR, Rowland KM Jr, North Central Cancer Treatment Group: Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. Ann Oncol; 2006 Jan;17(1):29-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group.
  • We therefore undertook this phase II study to test this first-line combination in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia.
  • CONCLUSIONS: Oxaliplatin and capecitabine in combination demonstrates activity in metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16303863.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-15083; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-35113; United States / NCI NIH HHS / CA / CA-35119; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / CA-35267; United States / NCI NIH HHS / CA / CA-35269; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-52352; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-63826
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


28. Miyazaki K, Satoh H, Sekizawa K: Metastasis to appendix from lung adenocarcinoma. Int J Gastrointest Cancer; 2005;36(1):59-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis to appendix from lung adenocarcinoma.
  • We previously read with interest the case report by Filik et al. (International Journal of Gastrointestinal Cancer, 2003;34:55-58) on appendicular metastases from pancreatic adenocarcinoma.
  • His past medical history included a pneumonectomy of the left lung for locally advanced lung adenocarcinoma 9 mo previously.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Int J Gastrointest Cancer. 2003;34(1):55-8 [15235136.001]
  • [Cites] Pathol Int. 1996 Mar;46(3):216-20 [10846573.001]
  • [Cites] Int J Gastrointest Cancer. 2003;34(1):55-8 [15235136.001]
  • [Cites] Dis Colon Rectum. 1970 Jul-Aug;13(4):336-40 [5459822.001]
  • (PMID = 16227637.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Mlakar V, Strazisar M, Sok M, Glavac D: Oligonucleotide DNA microarray profiling of lung adenocarcinoma revealed significant downregulation and deletions of vasoactive intestinal peptide receptor 1. Cancer Invest; 2010 Jun;28(5):487-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oligonucleotide DNA microarray profiling of lung adenocarcinoma revealed significant downregulation and deletions of vasoactive intestinal peptide receptor 1.
  • The purpose of this study was to find novel gene(s) involved in the development of lung adenocarcinoma (AD).
  • Using DNA microarrays, we identified 31 up-regulated and 8 downregulated genes in 12 AD.
  • Real time PCR was used to measure expression of VIPR1 and SPP1 mRNA and possible losses or gains of genes in 32 AD.
  • [MeSH-major] Adenocarcinoma / genetics. Lung Neoplasms / genetics. Receptors, Vasoactive Intestinal Polypeptide, Type I / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20014941.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Vasoactive Intestinal Polypeptide, Type I; 0 / SPP1 protein, human; 106441-73-0 / Osteopontin
  •  go-up   go-down


30. Jamieson NB, Glen P, McMillan DC, McKay CJ, Foulis AK, Carter R, Imrie CW: Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer; 2005 Jan 17;92(1):21-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas.
  • The aim of the present study was to examine the relationship between the clinicopathological status, the pre- and postoperative systemic inflammatory response and survival in patients undergoing potentially curative resection for ductal adenocarcinoma of the head of the pancreas.
  • Patients (n = 65) who underwent resection of ductal adenocarcinoma of the head of pancreas between 1993 and 2001, and had pre- and postoperative measurements of C-reactive protein, were included in the study.
  • The majority of patients had stage III disease (International Union Against Cancer Criteria, IUCC), positive circumferential margin involvement (R1), tumour size greater than 25 mm with perineural and lymph node invasion and died within the follow-up period.
  • The results of the present study indicate that, in patients who have undergone potentially curative resection for ductal adenocarcinoma of the head of pancreas, the presence of a systemic inflammatory response predicts poor outcome.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nutr Cancer. 2000;37(1):36-40 [10965517.001]
  • [Cites] Surg Today. 1999;29(1):16-22 [9934826.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • [Cites] Curr Oncol Rep. 2002 May;4(3):250-5 [11937016.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Br J Surg. 2003 Feb;90(2):215-9 [12555298.001]
  • [Cites] Eur J Surg Oncol. 2003 May;29(4):368-73 [12711291.001]
  • [Cites] Ann Surg. 2003 Aug;238(2):197-202 [12894012.001]
  • [Cites] Br J Cancer. 2004 May 4;90(9):1707-9 [15150596.001]
  • [Cites] Anticancer Res. 1994 Mar-Apr;14(2B):657-66 [8010724.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2077-82 [7535184.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] CA Cancer J Clin. 1996 Jan-Feb;46(1):5-27 [8548526.001]
  • [Cites] Ann Surg. 1996 Feb;223(2):147-53 [8597508.001]
  • [Cites] Langenbecks Arch Surg. 1998 Apr;383(2):116-20 [9641883.001]
  • [Cites] Oncology. 2000 Nov;59(4):296-301 [11096341.001]
  • (PMID = 15597096.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9007-41-4 / C-Reactive Protein
  • [Other-IDs] NLM/ PMC2361749
  •  go-up   go-down


31. Sjödahl K, Lagergren J: Epidemiological aspects of gastric adenocarcinoma: are predictive diagnostics and targeted preventive measures possible? EPMA J; 2010 Sep;1(3):461-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiological aspects of gastric adenocarcinoma: are predictive diagnostics and targeted preventive measures possible?
  • Furthermore, it can add to the understanding of malignant disease and prevention in general.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Best Pract Res Clin Gastroenterol. 2006;20(4):633-49 [16997150.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Nov;6(11):863-73 [9367058.001]
  • [Cites] Int J Cancer. 1995 Mar 3;60(5):642-4 [7860138.001]
  • [Cites] Gut. 2007 Jul;56(7):918-25 [17317788.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):456-63 [15455378.001]
  • [Cites] Int J Cancer. 2005 Jan 1;113(1):148-57 [15386435.001]
  • [Cites] Int J Cancer. 1991 Feb 20;47(4):499-503 [1995480.001]
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):446-9 [11920598.001]
  • [Cites] Int J Epidemiol. 1996 Jun;25(3):494-504 [8671549.001]
  • [Cites] Postgrad Med J. 2006 May;82(967):338-42 [16679473.001]
  • [Cites] Cancer Causes Control. 2005 Sep;16(7):773-80 [16132787.001]
  • [Cites] Lancet Oncol. 2003 Jan;4(1):45-55 [12517539.001]
  • [Cites] Br Med Bull. 2008;85:87-100 [18267927.001]
  • [Cites] Am J Gastroenterol. 1999 Sep;94(9):2373-9 [10483994.001]
  • [Cites] Eur J Epidemiol. 2004;19(9):821-2 [15499891.001]
  • [Cites] Int J Cancer. 2000 Jul 1;87(1):133-40 [10861464.001]
  • [Cites] Br J Cancer. 2006 Jan 16;94(1):136-41 [16404367.001]
  • [Cites] Lancet Oncol. 2009 May;10(5):501-7 [19410194.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1784-91 [14652240.001]
  • [Cites] World J Gastroenterol. 2006 May 21;12(19):2991-9 [16718777.001]
  • [Cites] J Nutr. 2002 Nov;132(11 Suppl):3456S-3464S [12421870.001]
  • [Cites] Eur J Cancer. 2008 Feb;44(3):465-71 [18221867.001]
  • [Cites] Eur J Surg. 2000 Oct;166(10):787-95 [11071166.001]
  • [Cites] FEMS Immunol Med Microbiol. 2007 Jul;50(2):146-56 [17442014.001]
  • [Cites] Br J Nutr. 1999 May;81(5):349-58 [10615207.001]
  • [Cites] Scand J Infect Dis. 2006;38(6-7):407-17 [16798686.001]
  • [Cites] Lancet. 1975 Jul 12;2(7924):58-60 [49653.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):659-72 [17681184.001]
  • [Cites] Gastric Cancer. 2004;7(4):211-20 [15616769.001]
  • [Cites] Mutat Res. 1988 Dec;202(2):307-24 [3057363.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Ann Nutr Metab. 2002;46(3-4):103-7 [12169852.001]
  • [Cites] Am J Prev Med. 2009 Feb;36(2):112-9 [19062237.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3030-44 [16404738.001]
  • [Cites] Ann Oncol. 2008 Nov;19(11):1894-902 [18628242.001]
  • [Cites] JAMA. 2004 Jan 14;291(2):187-94 [14722144.001]
  • [Cites] Gut. 2001 Sep;49(3):347-53 [11511555.001]
  • [Cites] Int J Cancer. 1994 Apr 1;57(1):32-7 [8150538.001]
  • [Cites] Int J Cancer. 2000 May 1;86(3):421-4 [10760832.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] N Engl J Med. 1996 May 2;334(18):1145-9 [8602179.001]
  • [Cites] Int J Cancer. 1999 Oct 8;83(2):223-9 [10471531.001]
  • [Cites] Int J Cancer. 2003 Oct 10;106(6):953-60 [12918076.001]
  • [Cites] N Engl J Med. 2000 Jul 13;343(2):78-85 [10891514.001]
  • [Cites] Lancet. 1997 May 3;349(9061):1269-76 [9142060.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Int J Cancer. 2003 Jul 10;105(5):692-700 [12740920.001]
  • [Cites] Cancer. 1993 Feb 1;71(3):745-50 [8431855.001]
  • [Cites] Helicobacter. 2000;5 Suppl 1:S3-9; discussion S27-31 [10828748.001]
  • [Cites] Epidemiol Rev. 1996;18(2):218-34 [9021314.001]
  • [Cites] Br J Cancer. 2009 Feb 10;100(3):551-7 [19156150.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):135-40 [18187390.001]
  • [Cites] Int J Cancer. 2009 Aug 1;125(3):666-73 [19382179.001]
  • [Cites] Basic Clin Pharmacol Toxicol. 2006 Mar;98(3):281-7 [16611203.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):287-301 [11319168.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 18;98(20):1432-4 [17047185.001]
  • [Cites] Gastric Cancer. 2007;10(2):75-83 [17577615.001]
  • [Cites] Int J Cancer. 2002 Feb 20;97(6):833-8 [11857364.001]
  • [Cites] Am J Epidemiol. 2009 Aug 15;170(4):507-14 [19584132.001]
  • [Cites] World J Gastroenterol. 2006 Jan 21;12(3):354-62 [16489633.001]
  • [Cites] Gut. 2006 Nov;55(11):1538-44 [16785284.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Dec;5(12):1413-7, 1417.e1-2 [17997357.001]
  • [Cites] Int J Cancer. 1994 Jun 1;57(5):638-44 [8194870.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Mar;23(3):351-65 [18318820.001]
  • [Cites] J Clin Biochem Nutr. 2008 Mar;42(2):71-5 [18385822.001]
  • [Cites] Gastroenterology. 2000 Jul;119(1):7-14 [10889149.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):340-6 [10652424.001]
  • [Cites] Int J Cancer. 2001 Aug 1;93(3):417-23 [11433408.001]
  • [Cites] Aliment Pharmacol Ther. 1999 Jul;13(7):851-6 [10383517.001]
  • [Cites] Br J Cancer. 2009 May 5;100(9):1503-7 [19352380.001]
  • [Cites] World J Gastroenterol. 2009 May 14;15(18):2204-13 [19437559.001]
  • [Cites] J Clin Pathol. 1998 May;51(5):410-2 [9708215.001]
  • [Cites] Am J Public Health. 2005 Aug;95(8):1396-402 [15985645.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Apr;4(4):416-25 [16616344.001]
  • [Cites] Gastric Cancer. 2002;5(4):213-9 [12491079.001]
  • [Cites] Dermatol Clin. 1995 Jan;13(1):65-71 [7712652.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2006 Aug;18(8):821-9 [16825897.001]
  • [Cites] Gastroenterology. 2001 Oct;121(4):784-91 [11606491.001]
  • [Cites] Cancer Causes Control. 2001 Jan;12(1):13-21 [11227921.001]
  • [Cites] Occup Environ Med. 2002 May;59(5):329-37 [11983848.001]
  • [Cites] Br J Ind Med. 1990 May;47(5):298-301 [2357449.001]
  • [Cites] Int J Cancer. 1997 Aug 7;72(4):565-73 [9259392.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1472-89 [10995803.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Oct-Nov;3(7):607-11 [7827592.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6735-40 [1458460.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Sep;5(9):673-7 [8877056.001]
  • [Cites] J Gastroenterol Hepatol. 2003 May;18(5):534-9 [12702045.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006;20(4):687-96 [16997153.001]
  • [Cites] Infect Immun. 1998 Jun;66(6):2943-50 [9596771.001]
  • [Cites] Science. 2004 Nov 26;306(5701):1568-71 [15567866.001]
  • [Cites] J Natl Cancer Inst. 2000 Dec 6;92(23):1881-8 [11106679.001]
  • [Cites] J Clin Pathol. 1994 Aug;47(8):695-8 [7962618.001]
  • [Cites] Postgrad Med J. 2003 May;79(931):252-8 [12782770.001]
  • [Cites] Arch Intern Med. 1990 Oct;150(10):2022-6 [2222087.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Am J Clin Nutr. 1995 Dec;62(6 Suppl):1424S-1426S [7495242.001]
  • [Cites] Lancet. 2008 Aug 2;372(9636):392-7 [18675689.001]
  • [Cites] Jpn J Clin Oncol. 2008 Jan;38(1):8-25 [18258712.001]
  • [Cites] Cancer Causes Control. 2008 Sep;19(7):689-701 [18293090.001]
  • [Cites] World J Gastroenterol. 2003 Dec;9(12):2658-61 [14669307.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1201-5 [11700269.001]
  • [Cites] Gastroenterology. 2007 Sep;133(3):985-1001 [17854602.001]
  • [Cites] Cancer Causes Control. 1996 Jan;7(1):41-55 [8850434.001]
  • [Cites] Cancer Causes Control. 2005 Apr;16(3):285-94 [15947880.001]
  • [Cites] J Clin Epidemiol. 2003 Jan;56(1):1-9 [12589864.001]
  • [Cites] Clin Microbiol Rev. 2006 Jul;19(3):449-90 [16847081.001]
  • [Cites] J Natl Cancer Inst. 1968 Jan;40(1):43-68 [5635018.001]
  • [Cites] Lancet. 1984 Jun 16;1(8390):1311-5 [6145023.001]
  • [Cites] J Clin Gastroenterol. 1981;3(Suppl 2):23-7 [7320466.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):458-66 [16049963.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Int J Cancer. 2004 Dec 20;112(6):1049-55 [15386347.001]
  • [Cites] Crit Rev Food Sci Nutr. 1995 Jan;35(1-2):59-64 [7748480.001]
  • [Cites] World J Surg. 2000 Mar;24(3):315-20 [10658066.001]
  • [Cites] Gastric Cancer. 2006;9(4):245-53 [17235625.001]
  • [Cites] Radiat Res. 1994 Feb;137(2 Suppl):S17-67 [8127952.001]
  • [Cites] N Engl J Med. 2001 Sep 13;345(11):784-9 [11556297.001]
  • [Cites] Int J Cancer. 2002 Nov 1;102(1):39-44 [12353232.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):128-32 [17036324.001]
  • [Cites] Gut. 1995 Jan;36(1):12-6 [7890214.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):4-10 [14744726.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241 [7715068.001]
  • [Cites] Int J Cancer. 2003 Nov 20;107(4):629-34 [14520702.001]
  • [Cites] Public Health. 2000 Sep;114(5):308-15 [11035446.001]
  • [Cites] Gastroenterology. 1998 Jun;114(6):1169-79 [9609753.001]
  • [Cites] Ann Surg. 2006 Apr;243(4):479-85 [16552198.001]
  • [Cites] Acta Pathol Microbiol Scand. 1951;29(1):26-44 [14902458.001]
  • [Cites] Br J Cancer. 2001 Nov 2;85(9):1311-6 [11720466.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] Gastroenterology. 2003 May;124(5):1193-201 [12730860.001]
  • [Cites] Sports Med. 2006;36(4):327-58 [16573358.001]
  • [Cites] Int J Cancer. 1968 Nov 15;3(6):809-18 [5731983.001]
  • [Cites] Biol Chem. 2006 Apr;387(4):361-4 [16606332.001]
  • [Cites] Int J Epidemiol. 2007 Feb;36(1):66-76 [17227779.001]
  • [Cites] Eur J Cancer. 2008 May;44(7):1007-14 [18394879.001]
  • [Cites] Gut. 1991 Jul;32(7):740-4 [1855679.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):2013-8 [17266028.001]
  • [Cites] Arch Pathol Lab Med. 1998 Jan;122(1):9-14 [9448011.001]
  • [Cites] J Natl Cancer Inst. 2007 Jan 17;99(2):137-46 [17227997.001]
  • [Cites] Am J Epidemiol. 1989 Sep;130(3):522-9 [2763997.001]
  • [Cites] Gastroenterology. 2002 Oct;123(4):985-91 [12360458.001]
  • [Cites] Helicobacter. 2008 Apr;13(2):146-56 [18321304.001]
  • [Cites] Mol Pathol. 2000 Oct;53(5):255-61 [11091849.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2007;21(2):205-14 [17382273.001]
  • [Cites] Br Med J. 1953 Apr 11;1(4814):799-801 [13032504.001]
  • [Cites] Int J Cancer. 2006 Sep 15;119(6):1217-23 [16557568.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1920-8 [17035400.001]
  • [Cites] Ann Intern Med. 2000 Aug 1;133(3):165-75 [10906830.001]
  • [Cites] World J Gastroenterol. 2006 Jan 14;12(2):199-203 [16482618.001]
  • [Cites] N Engl J Med. 2004 Sep 9;351(11):1137-42 [15356313.001]
  • [Cites] Cancer Causes Control. 1991 Jul;2(4):227-33 [1873452.001]
  • [Cites] Lancet. 2003 Jul 26;362(9380):305-15 [12892963.001]
  • (PMID = 23199088.001).
  • [ISSN] 1878-5077
  • [Journal-full-title] The EPMA journal
  • [ISO-abbreviation] EPMA J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3405336
  •  go-up   go-down


32. Miller JS, Chen Y, Ye H, Robinson BD, Brimo F, Epstein JI: Extraprostatic extension of prostatic adenocarcinoma on needle core biopsy: report of 72 cases with clinical follow-up. BJU Int; 2010 Aug;106(3):330-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraprostatic extension of prostatic adenocarcinoma on needle core biopsy: report of 72 cases with clinical follow-up.
  • OBJECTIVE: To describe the histological findings and prognosis that are associated with extraprostatic extension (EPE) on needle core biopsy of prostatic adenocarcinoma.
  • PATIENTS AND METHODS: We retrieved 99 cases of prostatic adenocarcinoma with EPE at initial diagnosis on biopsy from the consultation files of one of the authors between 1997 and 2009.
  • The mean (range) number of malignant cores was 7.7 (1-23); the mean percentage of carcinoma in each core was 69.6%, and that in the core(s) with EPE was 76.8%.
  • Patients were followed for a mean (median, range) of 2.9 (2, 0.1-9) years, with metastases identified in 29 (40%); 10 (14%) died from the disease.
  • CONCLUSION: EPE on needle core biopsy of the prostate is strongly associated with extensive, high-grade prostatic adenocarcinoma, such that its usefulness as an isolated prognostic factor is relatively limited.
  • [MeSH-major] Adenocarcinoma / pathology. Prostate / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20002671.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


33. Al-Salam S, Al-Ashari M: Expression of Galectin-3, CD138, p16INK4a, and TTF-1 in mucinous bronchioloalveolar adenocarcinoma after Hodgkin lymphoma. Appl Immunohistochem Mol Morphol; 2009 Jul;17(4):351-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Galectin-3, CD138, p16INK4a, and TTF-1 in mucinous bronchioloalveolar adenocarcinoma after Hodgkin lymphoma.
  • Bronchioloalveolar carcinoma (BAC) is a subset of lung adenocarcinoma that has a distinct clinical presentation, tumor biology, response to therapy, and prognosis compared with other subtypes of non-small-cell lung carcinoma.
  • We describe a case of young female who received radiation therapy to the mediastinum and chemotherapy for Hodgkin lymphoma and now develops mucinous bronchioalveolar adenocarcinoma of the left lung which to the best of our knowledge has not been previously described after radiotherapy and chemotherapy for Hodgkin lymphoma.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18997617.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Galectin 3; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


34. Fernández Rosado E, Sánchez Rodríguez-Losada J, Chantada Abal V, Rois Soto JM: [Nephron sparing renal surgery as salvage treatment after failure of radiofrequency thermal ablation in a patient with a single kidney and renal adenocarcinoma]. Arch Esp Urol; 2006 Jul-Aug;59(6):577-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nephron sparing renal surgery as salvage treatment after failure of radiofrequency thermal ablation in a patient with a single kidney and renal adenocarcinoma].
  • [Transliterated title] Cirugía renal conservadora de nefronas como tratamiento de rescate tras fracaso de la termoablación mediante radiofrecuencia en paciente monorreno con adenocarcinoma renal.
  • Case report of a successful nephron-sparing surgery after failure of the RF thermal ablation of a renal adenocarcinoma in a patient with a single kidney.
  • METHODS: A patient presenting with a renal adenocarcinoma in a single left kidney was treated by RF thermal ablation.
  • Pathology report: renal adenocarcinoma with changes secondary to central necrosis.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / surgery. Catheter Ablation. Kidney / abnormalities. Kidney / surgery. Kidney Neoplasms / complications. Kidney Neoplasms / surgery. Nephrectomy / methods

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933485.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


35. Johansson J, Djerf P, Oberg S, Zilling T, von Holstein CS, Johnsson F, Walther B: Two different surgical approaches in the treatment of adenocarcinoma at the gastroesophageal junction. World J Surg; 2008 Jun;32(6):1013-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two different surgical approaches in the treatment of adenocarcinoma at the gastroesophageal junction.
  • BACKGROUND: Adenocarcinoma at the gastroesophageal junction may be regarded as of esophageal or of gastric origin, and tumor removal may follow the principles of esophagectomy or extended gastrectomy.
  • CONCLUSIONS: Provided that adequate tumor dissection is performed, patients with adenocarcinoma at the gastroesophageal junction can be resected and reconstructed using the principles for esophagectomy or extended gastrectomy.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagogastric Junction / surgery. Stomach Neoplasms / surgery


36. Salihoğlu Y, Keskin N, Topuz S, Küçücük S, Iyibozkurt C: Analysis of vaginal recurrences in stage I endometrial adenocarcinoma. Eur J Gynaecol Oncol; 2007;28(4):313-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of vaginal recurrences in stage I endometrial adenocarcinoma.
  • RESULTS: Overall 5-year survival rate for all patients with Stage I disease was 80%.
  • Nine patients (6.25%) developed recurrent disease, three of whom had vaginal recurrences.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Squamous Cell / pathology. Endometrial Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Vagina / pathology
  • [MeSH-minor] Cohort Studies. Female. Humans. Myometrium / pathology. Neoplasm Invasiveness. Neoplasm Staging. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17713101.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


37. Tsang H, Yau T, Khong PL, Epstein RJ: Bevacizumab-based therapy for advanced small bowel adenocarcinoma. Gut; 2008 Nov;57(11):1631-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab-based therapy for advanced small bowel adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Intestinal Neoplasms / drug therapy. Intestine, Small

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gut. 2010 Nov;59(11):1587-8 [20732917.001]
  • (PMID = 18941013.001).
  • [ISSN] 1468-3288
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Transforming Growth Factor beta1; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


38. Stokrová J, Sloncová E, Sovová V, Kucerová D, Zíla V, Turecková J, Vojtechová M, Korb J, Tuhácková Z: Characterization of four clones derived from human adenocarcinoma cell line, HT29, and analysis of their response to sodium butyrate. Int J Oncol; 2006 Feb;28(2):559-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of four clones derived from human adenocarcinoma cell line, HT29, and analysis of their response to sodium butyrate.
  • Several adenocarcinoma cell lines, including HT29 which differentiates only upon stimulation with a differentiation agent, have been used for the study of colorectal cells.
  • [MeSH-minor] Adenocarcinoma. Alkaline Phosphatase / metabolism. Antigens, CD / metabolism. Apoptosis. Cell Adhesion Molecules / metabolism. Cell Differentiation / drug effects. Clone Cells. Colorectal Neoplasms. Humans. p38 Mitogen-Activated Protein Kinases / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16391813.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Butyrates; 0 / CD66 antigens; 0 / Cell Adhesion Molecules; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


39. Reyes Court D, Encina S, Levy I: Prostatic adenocarcinoma with mandibular metastatic lesion: case report. Med Oral Patol Oral Cir Bucal; 2007 Oct;12(6):E424-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostatic adenocarcinoma with mandibular metastatic lesion: case report.
  • Differential diagnosis and treatment of these patients can be extremely difficult because there a number of pathologic conditions with similar symptoms and because diagnostic examination can be highly confusing.
  • The aim of this article is to present a case of prostatic adenocarcinoma where the only metastasis was found in the jaw.
  • [MeSH-major] Adenocarcinoma / secondary. Mandibular Neoplasms / secondary. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909506.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 13
  •  go-up   go-down


40. Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW, Whang EE: RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance. Clin Cancer Res; 2005 May 1;11(9):3433-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance.
  • We examined the role of ILK in determining pancreatic adenocarcinoma cellular chemoresistance to the nucleoside analogue gemcitabine.
  • Levels of ILK expression affect gemcitabine chemoresistance in pancreatic adenocarcinoma cells.
  • This novel finding suggests that therapies directed against ILK and its downstream signaling targets may have the potential to enhance the efficacy of gemcitabine-based chemotherapy.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. L-SERINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 Sep 7;19(38):4319-27 [10980607.001]
  • [Cites] Br J Cancer. 2003 Jun 2;88(11):1755-62 [12771992.001]
  • [Cites] J Cell Biol. 2000 Oct 30;151(3):483-94 [11062251.001]
  • [Cites] Oncogene. 2000 Nov 16;19(48):5444-52 [11114721.001]
  • [Cites] Oncogene. 2001 Jan 4;20(1):133-40 [11244511.001]
  • [Cites] Leuk Lymphoma. 2001 Feb;40(5-6):631-45 [11426535.001]
  • [Cites] Leukemia. 2001 Aug;15(8):1232-9 [11480565.001]
  • [Cites] Oncogene. 2001 Sep 27;20(43):6250-7 [11593435.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3269-75 [11595724.001]
  • [Cites] Mol Cancer Ther. 2002 Oct;1(12):989-97 [12481421.001]
  • [Cites] EMBO Rep. 2003 Apr;4(4):432-8 [12671688.001]
  • [Cites] Genes Dev. 2003 Apr 1;17(7):926-40 [12670870.001]
  • [Cites] Mol Cell Biol. 1999 Nov;19(11):7420-7 [10523630.001]
  • [Cites] Br J Cancer. 2003 May 6;88(9):1470-9 [12778079.001]
  • [Cites] J Biol Chem. 2003 Jun 20;278(25):22374-8 [12686550.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):391-7 [12865934.001]
  • [Cites] Int J Mol Med. 2003 Nov;12(5):693-700 [14532995.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Nov 21;311(3):786-92 [14623342.001]
  • [Cites] Pancreas. 2004 Jan;28(1):38-44 [14707728.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):79-90 [14749128.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):453-62 [14751515.001]
  • [Cites] Oncogene. 2004 Feb 26;23(8):1539-48 [14661056.001]
  • [Cites] Pancreas. 1990 May;5(3):267-77 [2111548.001]
  • [Cites] Nature. 1996 Jan 4;379(6560):91-6 [8538749.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Curr Opin Oncol. 1997 Nov;9(6):549-56 [9370076.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4374-9 [9539744.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11211-6 [9736715.001]
  • [Cites] Science. 1998 Nov 13;282(5392):1318-21 [9812896.001]
  • [Cites] Blood. 1999 Mar 1;93(5):1658-67 [10029595.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1587-94 [10389948.001]
  • [Cites] Oncogene. 2000 Aug 3;19(33):3811-5 [10949937.001]
  • [Cites] Curr Opin Cell Biol. 2000 Apr;12(2):250-6 [10712922.001]
  • [Cites] Oncogene. 1999 Dec 23;18(56):8024-32 [10637513.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5451-5 [11034087.001]
  • (PMID = 15867245.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA114103-01; United States / NCI NIH HHS / CA / R01 CA114103-01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Proto-Oncogene Proteins; 0 / RNA, Small Interfering; 0W860991D6 / Deoxycytidine; 452VLY9402 / Serine; B76N6SBZ8R / gemcitabine; EC 2.7.1.- / integrin-linked kinase; EC 2.7.11.- / Glycogen Synthase Kinases; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ NIHMS84388; NLM/ PMC2734187
  •  go-up   go-down


41. Nakata M, Miwa Y, Nakayama H, Sakai T, Sasaki N: Localised radiotherapy for a ferret with possible anal sac apocrine adenocarcinoma. J Small Anim Pract; 2008 Sep;49(9):476-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localised radiotherapy for a ferret with possible anal sac apocrine adenocarcinoma.
  • On histopathology, the masses were diagnosed as apocrine adenocarcinoma possibly of anal gland origin based on tumour location.
  • Cytology of a sample of the pleural effusion suggested mesothelioma, and no obvious pulmonary metastasis of anal sac adenocarcinoma were identified on thoracic radiography.
  • [MeSH-major] Adenocarcinoma / veterinary. Anal Gland Neoplasms / radiotherapy. Anal Sacs. Ferrets
  • [MeSH-minor] Animals. Fatal Outcome. Male. Mesothelioma / radiography. Mesothelioma / surgery. Mesothelioma / veterinary. Neoplasm Recurrence, Local / radiography. Neoplasm Recurrence, Local / surgery. Neoplasm Recurrence, Local / veterinary. Neoplasms, Second Primary / radiography. Neoplasms, Second Primary / surgery. Neoplasms, Second Primary / veterinary. Pleural Effusion / etiology. Pleural Effusion / radiography. Pleural Effusion / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18631226.001).
  • [ISSN] 0022-4510
  • [Journal-full-title] The Journal of small animal practice
  • [ISO-abbreviation] J Small Anim Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


42. Bansal A, Pradeep KE, Gumparthy KP: An unusual case of low-grade tubulopapillary adenocarcinoma of the sinonasal tract. World J Surg Oncol; 2008;6:54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of low-grade tubulopapillary adenocarcinoma of the sinonasal tract.
  • BACKGROUND: Low-grade papillary adenocarcinomas of the sinonasal tract are rare neoplasms.
  • The biopsy revealed low-grade, non-intestinal type sinonasal tubulopapillary adenocarcinoma.
  • However, this raises the possibility of the utility of this antibody to predict a better clinical outcome in the subset of low grade non-intestinal sinonasal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Paranasal Sinus Neoplasms / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2003 Aug;443(2):152-8 [12827515.001]
  • [Cites] Histopathology. 2004 Sep;45(3):254-9 [15330803.001]
  • [Cites] Cancer. 1982 Jul 15;50(2):312-22 [7083137.001]
  • [Cites] Histopathology. 2006 Jun;48(7):881-4 [16722945.001]
  • [Cites] Am J Surg Pathol. 1991 Apr;15(4):368-75 [2006716.001]
  • [Cites] Acta Oncol. 1997;36(1):45-50 [9090965.001]
  • [Cites] Arch Otorhinolaryngol. 1985;241(2):183-93 [3977770.001]
  • (PMID = 18492272.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / TTF1 protein, human
  • [Other-IDs] NLM/ PMC2426684
  •  go-up   go-down


43. An JY, Kim JY, Choi MG, Noh JH, Choi D, Sohn TS, Kim S: Radiofrequency ablation for hepatic metastasis from gastric adenocarcinoma. Yonsei Med J; 2008 Dec 31;49(6):1046-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation for hepatic metastasis from gastric adenocarcinoma.
  • We present our preliminary findings from 4 cases of liver metastasis from gastric adenocarcinomas treated using radiofrequency ablation (RFA).
  • Although this study was limited to a few cases and had a short follow-up duration, our findings suggest that RFA may provide an alternative treatment modality for liver metastasis resulting from gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Catheter Ablation / methods. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterol Clin Biol. 1999 Nov;23(11):1128-33 [10651531.001]
  • [Cites] Surg Gynecol Obstet. 1989 Oct;169(4):371-85 [2476864.001]
  • [Cites] Surg Today. 2000;30(11):1041-5 [11110405.001]
  • [Cites] Am J Surg. 2001 Mar;181(3):279-83 [11376587.001]
  • [Cites] Radiology. 2001 Oct;221(1):159-66 [11568334.001]
  • [Cites] Ann Surg. 2002 Jan;235(1):86-91 [11753046.001]
  • [Cites] Arch Surg. 2002 Apr;137(4):422-6; discussion 427 [11926946.001]
  • [Cites] Hepatogastroenterology. 2002 Jul-Aug;49(46):1062-5 [12143202.001]
  • [Cites] J Gastrointest Surg. 2002 Sep-Oct;6(5):682-9 [12399057.001]
  • [Cites] Surgery. 2003 May;133(5):507-11 [12773978.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1560-3 [14571786.001]
  • [Cites] Am J Surg. 1980 Sep;140(3):356-9 [6158880.001]
  • [Cites] Hepatogastroenterology. 1997 May-Jun;44(15):897-900 [9222711.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 Oct;31(11):1737-9 [15553699.001]
  • [Cites] Ann Surg Oncol. 2005 Jun;12(6):459-66 [15886903.001]
  • [Cites] Am Surg. 2005 Feb;71(2):95-9 [16022005.001]
  • [Cites] Ann Ital Chir. 2005 Jan-Feb;76(1):39-41 [16035670.001]
  • [Cites] Semin Radiat Oncol. 2005 Oct;15(4):265-72 [16183480.001]
  • [Cites] J Vasc Interv Radiol. 2005 Dec;16(12):1747-51 [16371545.001]
  • [Cites] World J Gastroenterol. 2005 Oct 28;11(40):6395-401 [16419172.001]
  • [Cites] AJR Am J Roentgenol. 2000 Dec;175(6):1619-25 [11090390.001]
  • (PMID = 19108032.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2628018
  •  go-up   go-down


44. Wagner AD, Buechner-Steudel P, Wein A, Schmalenberg H, Lindig U, Moehler M, Behrens R, Kleber G, Kuss O, Fleig WE: Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Ann Oncol; 2007 Jan;18(1):82-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
  • This trial assessed efficacy and safety of the triple combination gemcitabine-oxaliplatin and infusional 5-FU in patients with locally advanced (n=11) or metastatic (n=32) pancreatic adenocarcinoma.
  • Nine patients were nonassessable for response because they did not complete the first two cycles of chemotherapy due to rapid disease progression, early death or treatment refusal.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17030546.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


45. Hisham RB, Thuaibah H, Gul YA: Mucinous adenocarcinoma of the rectum with breast and ocular metastases. Asian J Surg; 2006 Apr;29(2):95-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma of the rectum with breast and ocular metastases.
  • We present the case of a 32-year-old woman who, 10 months after abdominoperineal resection and total mesorectal excision for a locally advanced mucinous adenocarcinoma of the rectum, presented with local recurrence and metastases to the breast, spine, the left eye and orbit.
  • To the best of our knowledge, breast as well as ocular metastasis in a patient with mucinous adenocarcinoma of the rectum has never been reported and, therefore, needs to be documented.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16644510.001).
  • [ISSN] 1015-9584
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


46. Reinblatt M, Pin RH, Bowers WJ, Federoff HJ, Fong Y: Herpes simplex virus amplicon delivery of a hypoxia-inducible soluble vascular endothelial growth factor receptor (sFlk-1) inhibits angiogenesis and tumor growth in pancreatic adenocarcinoma. Ann Surg Oncol; 2005 Dec;12(12):1025-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Herpes simplex virus amplicon delivery of a hypoxia-inducible soluble vascular endothelial growth factor receptor (sFlk-1) inhibits angiogenesis and tumor growth in pancreatic adenocarcinoma.
  • A novel HSV amplicon expressing 10 x HRE/sFlk-1 was genetically engineered (HSV10 x HRE/sFlk-1).Human pancreatic adenocarcinoma cells (AsPC1) were transduced with HSV10 x HRE/sFlk-1 and incubated in normoxia (21% oxygen) or hypoxia (1% oxygen).
  • Tumor hypoxia can thus be used to direct antiangiogenic therapy to pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / therapy. Angiogenesis Inhibitors / administration & dosage. Hypoxia-Inducible Factor 1. Neovascularization, Physiologic / drug effects. Pancreatic Neoplasms / therapy. Vascular Endothelial Growth Factor Receptor-2 / administration & dosage

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16244806.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 76416; United States / NCI NIH HHS / CA / R01 CA/DK 80982
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Hypoxia-Inducible Factor 1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


47. Goulart BH, Clark JW, Lauwers GY, Ryan DP, Grenon N, Muzikansky A, Zhu AX: Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis. J Hematol Oncol; 2009;2:13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis.
  • BACKGROUND: Metastatic pancreatic adenocarcinoma has a short median overall survival (OS) of 5-6 months.
  • METHODS: We identified 20 patients with metastatic or recurrent pancreatic adenocarcinoma who received single-agent gemcitabine and had an OS longer than 1 year.
  • Baseline data available after the diagnosis of metastatic or recurrent disease was categorized as:.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / rehabilitation. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / rehabilitation. Survivors

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Mar;82(5):1013-6 [10737382.001]
  • [Cites] Am J Gastroenterol. 1999 May;94(5):1271-8 [10235206.001]
  • [Cites] Anticancer Res. 1999 Jul-Aug;19(4A):2433-5 [10470171.001]
  • [Cites] J Surg Oncol. 2000 Apr;73(4):212-8 [10797334.001]
  • [Cites] Oncol Rep. 2000 Jul-Aug;7(4):875-7 [10854561.001]
  • [Cites] Oncology. 2000 Nov;59(4):296-301 [11096341.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Acta Oncol. 2001;40(2-3):361-70 [11441941.001]
  • [Cites] Pancreas. 2002 Jan;24(1):15-25 [11741178.001]
  • [Cites] Am J Clin Oncol. 2001 Dec;24(6):547-50 [11801751.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):902-10 [11920457.001]
  • [Cites] Br J Cancer. 2002 Jul 15;87(2):161-7 [12107836.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3270-5 [12149301.001]
  • [Cites] Int J Gastrointest Cancer. 2002;32(1):35-41 [12630768.001]
  • [Cites] Eur J Cancer. 2003 Jul;39(10):1377-83 [12826040.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3402-8 [12885837.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2664-70 [15197810.001]
  • [Cites] Cancer. 1974 Feb;33(2):563-7 [4812773.001]
  • [Cites] Cancer. 1978 Nov;42(5):2494-506 [363259.001]
  • [Cites] Med J Aust. 1981 Apr 4;1(7):361-3 [7242420.001]
  • [Cites] J Clin Oncol. 1991 Sep;9(9):1682-6 [1875224.001]
  • [Cites] J Clin Oncol. 1991 Dec;9(12):2128-33 [1960554.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Digestion. 1997;58(6):503-7 [9438594.001]
  • [Cites] J Surg Oncol. 1998 Mar;67(3):151-9 [9530884.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • (PMID = 19291303.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  • [Other-IDs] NLM/ PMC2663565
  •  go-up   go-down


48. Hashimoto H, Oshika Y, Obara K, Tanaka Y, Shimizu E: [A dialysis patient with advanced lung adenocarcinoma who was safely given biweekly gemcitabine therapy]. Gan To Kagaku Ryoho; 2010 Aug;37(8):1553-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A dialysis patient with advanced lung adenocarcinoma who was safely given biweekly gemcitabine therapy].
  • We report our experience with gemcitabine safely administered to an elderly patient requiring hemodialysis who had advanced lung adenocarcinoma.
  • A diagnosis of Stage IIIB lung adenocarcinoma was made based on the findings of cytology from the pleural effusions and radiological examinations.
  • [MeSH-major] Adenocarcinoma / drug therapy. Deoxycytidine / analogs & derivatives. Kidney Failure, Chronic / therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Aged, 80 and over. Humans. Male. Neoplasm Staging. Renal Dialysis

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20716885.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


49. Badea L, Herlea V, Dima SO, Dumitrascu T, Popescu I: Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology; 2008 Nov-Dec;55(88):2016-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia.
  • BACKGROUND/AIMS: The precise details of pancreatic ductal adenocarcinoma (PDAC) pathogenesis are still insufficiently known, requiring the use of high-throughput methods.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Expression Regulation, Neoplastic. Oligonucleotide Array Sequence Analysis / methods. Pancreatic Neoplasms / genetics
  • [MeSH-minor] 14-3-3 Proteins. Annexin A2 / metabolism. Biomarkers, Tumor / metabolism. Exonucleases / metabolism. Exoribonucleases. Humans. Intracellular Signaling Peptides and Proteins / metabolism. Keratin-7 / metabolism. Laminin / metabolism. Membrane Proteins / metabolism. Microdissection. Neoplasm Proteins / metabolism. Phosphofructokinases / metabolism. Protein-Serine-Threonine Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19260470.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Annexin A2; 0 / Biomarkers, Tumor; 0 / Intracellular Signaling Peptides and Proteins; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / LAMC2 protein, human; 0 / Laminin; 0 / Membrane Proteins; 0 / Neoplasm Proteins; EC 2.7.1 - / Phosphofructokinases; EC 2.7.1.11 / MAP4K4 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 3.1.- / Exonucleases; EC 3.1.- / Exoribonucleases; EC 3.1.- / SFN protein, human
  •  go-up   go-down


50. Baatrup G, Elbrønd H, Hesselfeldt P, Wille-Jørgensen P, Møller P, Breum B, Qvist N: Rectal adenocarcinoma and transanal endoscopic microsurgery. Diagnostic challenges, indications and short term results in 142 consecutive patients. Int J Colorectal Dis; 2007 Nov;22(11):1347-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rectal adenocarcinoma and transanal endoscopic microsurgery. Diagnostic challenges, indications and short term results in 142 consecutive patients.
  • PURPOSE: The objective of this study was to present short-term results of transanal endoscopic microsurgery (TEM) of rectal adenocarcinomas registered in a national database.
  • In 43%of the patients, the cancer diagnosis was not recognized before TEM.
  • High ages were an indication for TEM in 22% and concurrent disease in 21%.
  • Multiple biopsies may be beneficial in the case of larger adenomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Microsurgery / methods. Proctoscopy / methods. Rectal Neoplasms / diagnosis. Rectal Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Gastroenterol Suppl. 2003;(239):34-9 [14743881.001]
  • [Cites] Chirurg. 1984 Oct;55(10):677-80 [6510078.001]
  • [Cites] Eur J Surg Oncol. 1986 Dec;12(4):373-7 [3780991.001]
  • [Cites] Gut. 1984 May;25(5):437-44 [6714785.001]
  • [Cites] Dig Surg. 2005;22(3):182-9; discussion 189-90 [16137996.001]
  • [Cites] Br J Surg. 2003 Aug;90(8):974-80 [12905551.001]
  • [Cites] Colorectal Dis. 2004 May;6(3):153-7 [15109377.001]
  • [Cites] Abdom Imaging. 2003 Nov-Dec;28(6):784-93 [14753591.001]
  • [Cites] BMJ. 2003 Nov 22;327(7425):1196-201 [14630754.001]
  • [Cites] Colorectal Dis. 2002 Nov;4(6):467-72 [12790922.001]
  • [Cites] Dis Colon Rectum. 2002 Feb;45(2):200-6 [11852333.001]
  • [Cites] Dis Colon Rectum. 2005 Jul;48(7):1380-8 [15906120.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Dec;19(6):993-1005 [16338654.001]
  • [Cites] Colorectal Dis. 2000 Sep;2(5):252-63 [23578114.001]
  • (PMID = 17643251.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


51. Wen C, Ying B, Zhang Y, Zhang J, Fan H: [Effect of quercetin on the expression and growth of caspase-3 in lung adenocarcinoma cancer cell line A549.]. Zhongguo Fei Ai Za Zhi; 2008 Apr 20;11(2):194-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of quercetin on the expression and growth of caspase-3 in lung adenocarcinoma cancer cell line A549.].
  • BACKGROUND: To study the influence of Quercetin in the expression of caspase-3 in Lung Adenocarcinoma Cancer cell line A549.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20731900.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


52. Zhao L, Shen ZX, Luo HS, Shen L: Possible involvement of leptin and leptin receptor in developing gastric adenocarcinoma. World J Gastroenterol; 2005 Dec 28;11(48):7666-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possible involvement of leptin and leptin receptor in developing gastric adenocarcinoma.
  • AIM: To investigate the expression of leptin and leptin receptor (ob-R) in intestinal-type gastric cancer and precancerous lesions, and to explore the possible mechanism and role of the leptin system in developing intestinal-type gastric adenocarcinoma.
  • METHODS: Immunohistochemistry was performed to examine the expression of leptin and leptin receptor in archival samples of gastric adenocarcinoma and preneoplastic lesions, including intestinal metaplasia and mild to severe gastric epithelial dysplasia.
  • RESULTS: Dual expression of leptin and leptin receptor were detected in 80% (16/20) intestinal metaplasia, 86.3% (25/30) mild gastric epithelial dysplasia, 86.7% (26/30) moderate gastric epithelial dysplasia, 93.3% (28/30) severe gastric epithelial dysplasia, 91.3% (55/60) intestinal-type gastric adenocarcinoma and 30.0% (9/30) diffuse-type gastric carcinoma.
  • The percentage of dual expression of leptin and leptin receptor in intestinal-type gastric adenocarcinoma was significantly higher than that in diffuse-type gastric adenocarcinoma (c2 = 37.022, P<0.01).
  • CONCLUSION: Our results indicate the presence of an autocrine loop of leptin system in the development of intestinal-type gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / etiology. Leptin / physiology. Receptors, Cell Surface / physiology. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437696.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Leptin; 0 / Receptors, Cell Surface; 0 / Receptors, Leptin; 0 / leptin receptor, human; EC 2.7.1.- / Phosphatidylinositol 3-Kinases
  • [Other-IDs] NLM/ PMC4727216
  •  go-up   go-down


53. Wang W, Reiser-Erkan C, Michalski CW, Raggi MC, Quan L, Yupei Z, Friess H, Erkan M, Kleeff J: Hypoxia inducible BHLHB2 is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Biochem Biophys Res Commun; 2010 Oct 22;401(3):422-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia inducible BHLHB2 is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma.
  • METHODS: Expression analyses were carried out in tissues of the normal pancreas (n=10) and pancreatic ductal adenocarcinoma (n=77) as well as in eight pancreatic cancer cell lines using quantitative RT-PCR, semiquantitative immunohistochemistry, and immunoblot analyses.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Basic Helix-Loop-Helix Transcription Factors / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Pancreatic Ductal / mortality. Deoxycytidine / analogs & derivatives. Drug Resistance, Neoplasm. Homeodomain Proteins / metabolism. Pancreatic Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20863812.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / BHLHE40 protein, human; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Biomarkers, Tumor; 0 / Homeodomain Proteins; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


54. Takami Y, Russell MB, Gao C, Mi Z, Guo H, Mantyh CR, Kuo PC: Sp1 regulates osteopontin expression in SW480 human colon adenocarcinoma cells. Surgery; 2007 Aug;142(2):163-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sp1 regulates osteopontin expression in SW480 human colon adenocarcinoma cells.
  • Using SW480 colon adenocarcinoma cells, we hypothesized that transcription determines OPN expression.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem J. 1994 Oct 1;303 ( Pt 1):255-62 [7945249.001]
  • [Cites] Am J Pathol. 1995 Jan;146(1):95-100 [7856741.001]
  • [Cites] FASEB J. 1993 Dec;7(15):1475-82 [8262332.001]
  • [Cites] Eur J Biochem. 1992 Jul 15;207(2):649-59 [1633816.001]
  • [Cites] Surgery. 1991 Jul;110(1):13-29 [1866690.001]
  • [Cites] Gene. 1991 Apr;100:163-71 [2055467.001]
  • [Cites] Cancer Res. 1988 Oct 15;48(20):5770-4 [3167835.001]
  • [Cites] J Cell Biochem. 1987 May;34(1):13-22 [3584260.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):448-56 [15170447.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):184-90 [14734468.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):233-41; discussion 241-2 [12892803.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jan;12(1):135-50 [12735135.001]
  • [Cites] Pathol Int. 2002 Jan;52(1):19-24 [11940202.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 3;94(7):513-21 [11929952.001]
  • [Cites] Cancer Treat Res. 2001;109:183-206 [11775436.001]
  • [Cites] J Biol Chem. 2006 Jul 14;281(28):18973-82 [16670084.001]
  • [Cites] Eur J Cancer. 2005 Nov;41(16):2438-48 [16209919.001]
  • [Cites] Carcinogenesis. 2005 Apr;26(4):741-51 [15661802.001]
  • [Cites] Exp Cell Res. 1999 Aug 1;250(2):535-47 [10413606.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):605-11 [9815727.001]
  • [Cites] Int J Cancer. 1997 Sep 4;72(5):739-45 [9311587.001]
  • [Cites] CA Cancer J Clin. 1996 Jan-Feb;46(1):5-27 [8548526.001]
  • [Cites] Am J Pathol. 1994 Sep;145(3):610-23 [8080043.001]
  • (PMID = 17689681.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R29 AI044629; United States / NIAID NIH HHS / AI / AI044629-06; United States / NIGMS NIH HHS / GM / GM65113; United States / NIGMS NIH HHS / GM / R56 GM065113; United States / NIGMS NIH HHS / GM / R01 GM065113-04; United States / NIDDK NIH HHS / DK / R21 DK070642; United States / NIDDK NIH HHS / DK / DK070642; United States / NIGMS NIH HHS / GM / GM065113-04; United States / NIAID NIH HHS / AI / R01 AI044629; United States / NIGMS NIH HHS / GM / R01 GM065113; United States / NIAID NIH HHS / AI / R29 AI044629-06; United States / NIDDK NIH HHS / DK / R21 DK070642-02; United States / NIAID NIH HHS / AI / AI44629; United States / NIDDK NIH HHS / DK / DK070642-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 0 / Sp1 Transcription Factor; 106441-73-0 / Osteopontin
  • [Other-IDs] NLM/ NIHMS28426; NLM/ PMC2174430
  •  go-up   go-down


55. Yoon GS, Wang W, Osunkoya AO, Lane Z, Partin AW, Epstein JI: Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma. J Urol; 2008 Jun;179(6):2203-6; discussion 2206
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma.
  • MATERIALS AND METHODS: We investigated 100 completely embedded radical prostatectomy specimens in which needle biopsy predicted limited disease (less than 3 positive cores, 50% or less involvement of any positive core, Gleason score 6 or less) and all positive needle cores were unilateral.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Technol Cancer Res Treat. 2004 Aug;3(4):365-70 [15270587.001]
  • [Cites] Urology. 2004 Oct;64(4):733-7 [15491711.001]
  • [Cites] Cancer. 1972 Jul;30(1):5-13 [5064808.001]
  • [Cites] Cancer. 1992 Nov 1;70(9):2313-8 [1382830.001]
  • [Cites] JAMA. 1994 Feb 2;271(5):368-74 [7506797.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):906-10 [17587207.001]
  • [Cites] Am J Surg Pathol. 1997 Feb;21(2):174-8 [9042283.001]
  • [Cites] Tech Urol. 1999 Sep;5(3):139-42 [10527256.001]
  • [Cites] J Endourol. 2006 Sep;20(9):688-92 [16999628.001]
  • [Cites] BJU Int. 2006 Nov;98(5):986-8 [17034600.001]
  • [Cites] Urology. 2007 Jun;69(6):1117-20 [17572198.001]
  • [Cites] J Urol. 1995 Mar;153(3 Pt 2):987-92 [7853589.001]
  • [CommentIn] J Urol. 2008 Jun;179(6):2091 [18423729.001]
  • (PMID = 18423736.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / P50 CA058236; United States / NCI NIH HHS / CA / CA 58236
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS374261; NLM/ PMC3353270
  •  go-up   go-down


56. Maykel JA, Hagerman G, Mellgren AF, Li SY, Alavi K, Baxter NN, Madoff RD: Crohn's colitis: the incidence of dysplasia and adenocarcinoma in surgical patients. Dis Colon Rectum; 2006 Jul;49(7):950-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Crohn's colitis: the incidence of dysplasia and adenocarcinoma in surgical patients.
  • The primary aim of our study was to determine the incidence of dysplasia and carcinoma in pathology specimens of patients undergoing segmental or total colectomy for Crohn's disease of the large bowel.
  • Logistic regression was used to model the probability of having dysplasia or adenocarcinoma.
  • Mean age at surgery was 41 (range, 15-82) years and the mean duration of disease was 10 (range, 0-53) years.
  • There were five cases of dysplasia (2.3 percent) and six cases of adenocarcinoma (2.7 percent).
  • Three patients with dysplasia and one with adenocarcinoma were diagnosed on preoperative colonoscopy; while the other cases were discovered incidentally on pathologic examination of resected specimens.
  • Factors associated with the presence of dysplasia or adenocarcinoma included older age at diagnosis (38.2 vs. 30.3 years, P = 0.02), longer disease duration (16.0 vs. 10.1 years, P = 0.05), and disease extent (90 percent extensive vs. 59 percent limited, P = 0.05).
  • CONCLUSIONS: Patients with severe Crohn's colitis requiring surgery are at significant risk for developing dysplasia and adenocarcinoma, particularly when diagnosed at an older age, after longer disease duration, and with more extensive colon involvement.
  • [MeSH-major] Adenocarcinoma / complications. Colitis / etiology. Colonic Neoplasms / complications. Crohn Disease / complications
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Colonoscopy. Female. Humans. Incidence. Logistic Models. Male. Middle Aged. Multivariate Analysis. Precancerous Conditions / diagnosis. Precancerous Conditions / epidemiology. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16729218.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Lee SK, Moon J, Park SW, Song SY, Chung JB, Kang JK: Loss of the tight junction protein claudin 4 correlates with histological growth-pattern and differentiation in advanced gastric adenocarcinoma. Oncol Rep; 2005 Feb;13(2):193-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of the tight junction protein claudin 4 correlates with histological growth-pattern and differentiation in advanced gastric adenocarcinoma.
  • Western blot analysis and RT-PCR also showed decreased claudin 4 expression in diffuse type tumors and poorly-differentiated adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Membrane Proteins / analysis. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adult. Blotting, Western. Cadherins / analysis. Cell Differentiation. Claudin-4. Disease Progression. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Phosphoproteins / analysis. Reverse Transcriptase Polymerase Chain Reaction. Zonula Occludens-1 Protein

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15643498.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / CLDN4 protein, human; 0 / Cadherins; 0 / Claudin-4; 0 / Membrane Proteins; 0 / Phosphoproteins; 0 / TJP1 protein, human; 0 / Zonula Occludens-1 Protein
  •  go-up   go-down


58. Wang WD, Chen ZT, Li R, Li DZ, Duan YZ, Cao ZH: Enhanced efficacy of radiation-induced gene therapy in mice bearing lung adenocarcinoma xenografts using hypoxia responsive elements. Cancer Sci; 2005 Dec;96(12):918-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced efficacy of radiation-induced gene therapy in mice bearing lung adenocarcinoma xenografts using hypoxia responsive elements.
  • The aim of the present study was to investigate whether the hypoxia responsive element (HRE) could be used to enhance suicide gene (HSV-tk) expression and tumoricidal activity in radiation-controlled gene therapy of human lung adenocarcinoma xenografts.
  • A human adenocarcinoma cell line (A549) was stably transfected with the above vectors using the lipofectamine method.
  • These results indicate that HRE can enhance transgene expression and tumoricidal activity in HSV-tk gene therapy controlled by ionizing radiation in hypoxic human lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Cell Hypoxia / radiation effects. Genetic Therapy / methods. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Animals. Apoptosis / drug effects. Apoptosis / radiation effects. Ganciclovir / therapeutic use. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Transplantation. Oxygen Consumption. Radiotherapy Dosage. Retroviridae / radiation effects. Transfection. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (Cancer Sci 2005; 96: 918 - 924).
  • (PMID = 16367913.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


59. Bîrla R, Iosif C, Gîndea C, Hoară P, Constantinoiu S: [Clinical diagnosis of adenocarcinoma of the esophago-gastric junction]. Chirurgia (Bucur); 2007 Sep-Oct;102(5):511-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical diagnosis of adenocarcinoma of the esophago-gastric junction].
  • [Transliterated title] Diagnosticul clinico-paraclinic al adenocarcinomului de joncţiune eso-gastrică.
  • The aim of the work paper is to present the diagnosis methods of the esophago-gastric junction adenocarcinoma, based on our experience and literature data.
  • The later reveal many novelties about diagnosis means in Barrett's esophagus (BE), the definition and classification of BE, as well as the progress of the endoscopical, immunohistochemical and molecular methods in surveillance of the dysplasia arising in BE and in detection of intraepithelial neoplasia.
  • Early esophago-gastric junction (EGJ) adenocarcinoma (AC) is asymptomatic and its detection may be possible only through endoscopical surveillance.
  • For this reason is necessary to use some more precise methods for identifying intestinal metaplasia on distal esophagus, in patients with gastro-esophageal reflux disease, as well as for risk stratification in patients with dysplasia and for detection of intraepithelial neoplasia.
  • Applying modern methods of immunohistochemical and molecular diagnosis on endoscopical biopsy or esophageal brushing samples, the diagnosis rate for BE, dysplasia and early AC is improved and using the imaging means permits to obtain preoperative TNM staging and tumoral type (Siewert), with implications in therapeutical management.
  • [MeSH-major] Adenocarcinoma / diagnosis. Esophageal Neoplasms / diagnosis. Esophagogastric Junction. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Barrett Esophagus / complications. Barrett Esophagus / pathology. Diagnosis, Differential. Humans. Neoplasm Staging. Risk Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018349.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 47
  •  go-up   go-down


60. Mijatovic T, Gailly P, Mathieu V, De Nève N, Yeaton P, Kiss R, Decaestecker C: Neurotensin is a versatile modulator of in vitro human pancreatic ductal adenocarcinoma cell (PDAC) migration. Cell Oncol; 2007;29(4):315-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurotensin is a versatile modulator of in vitro human pancreatic ductal adenocarcinoma cell (PDAC) migration.
  • METHODS: The NT-induced effects on the migration process of human pancreatic ductal adenocarcinoma cells (PDACs) were characterized by means of various assays including computer-assisted video-microscopy, fluorescence microscopy, ELISA-based, small GTPase pull-down and phosphorylation assays.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17641415.001).
  • [ISSN] 1570-5870
  • [Journal-full-title] Cellular oncology : the official journal of the International Society for Cellular Oncology
  • [ISO-abbreviation] Cell. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Actins; 0 / Integrin alphaV; 0 / Integrin beta Chains; 0 / Protein Subunits; 0 / Receptors, Neurotensin; 0 / Vitronectin; 0 / integrin beta5; 39379-15-2 / Neurotensin; EC 3.6.5.2 / cdc42 GTP-Binding Protein; EC 3.6.5.2 / rac1 GTP-Binding Protein; EC 3.6.5.2 / rho GTP-Binding Proteins
  • [Other-IDs] NLM/ PMC4618414
  •  go-up   go-down


61. Hamano T, Homma Y, Otsuki Y, Shimizu S, Kobayashi H, Kobayashi Y: Inguinal lymph node metastases are recognized with high frequency in rectal adenocarcinoma invading the dentate line. The histological features at the invasive front may predict inguinal lymph node metastasis. Colorectal Dis; 2010 Oct;12(10 Online):e200-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inguinal lymph node metastases are recognized with high frequency in rectal adenocarcinoma invading the dentate line. The histological features at the invasive front may predict inguinal lymph node metastasis.
  • The aim of this study was to identify risk factors for ILN metastasis in patients with low rectal adenocarcinoma.
  • METHOD: We retrospectively analysed 156 patients with lower rectal adenocarcinoma who underwent radical resection (R0) at a single institution.
  • The presence of poorly differentiated or mucinous adenocarcinoma components is an indication for bilateral groin irradiation.
  • [MeSH-major] Adenocarcinoma / secondary. Lymph Nodes / pathology. Rectal Neoplasms / pathology
  • [MeSH-minor] Aged. Female. Humans. Inguinal Canal. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Proportional Hazards Models. Retrospective Studies. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Colorectal Disease © 2010 The Association of Coloproctology of Great Britain and Ireland.
  • (PMID = 19912287.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


62. Galanis I, Chatzimavroudis G, Katsougiannopoulos A, Galanis N, Makris J, Atmatzidis K: Spermatic cord metastasis presenting as strangulated inguinal hernia - first manifestation of a multifocal colon adenocarcinoma: a case report. Cases J; 2009;2(1):61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spermatic cord metastasis presenting as strangulated inguinal hernia - first manifestation of a multifocal colon adenocarcinoma: a case report.
  • We herein report a case of spermatic cord metastasis of a previous undiagnosed multifocal colon adenocarcinoma, which was clinically presented as a strangulated groin hernia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Clin Pract. 2006 Dec;60(12):1681-2 [16836646.001]
  • [Cites] Jpn J Clin Oncol. 1994 Dec;24(6):340-4 [7830340.001]
  • [Cites] Histopathology. 2000 Oct;37(4):323-31 [11012739.001]
  • [Cites] Eur Urol. 1983;9(1):56-9 [6822245.001]
  • [Cites] Dig Surg. 2002;19(1):67-70 [11961361.001]
  • [Cites] J Urol. 1988 Sep;140(3):621-2 [3411689.001]
  • (PMID = 19149893.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2647912
  •  go-up   go-down


63. Chen YJ, Shieh CJ, Tsai TH, Kuo CD, Ho LT, Liu TY, Liao HF: Inhibitory effect of norcantharidin, a derivative compound from blister beetles, on tumor invasion and metastasis in CT26 colorectal adenocarcinoma cells. Anticancer Drugs; 2005 Mar;16(3):293-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory effect of norcantharidin, a derivative compound from blister beetles, on tumor invasion and metastasis in CT26 colorectal adenocarcinoma cells.
  • A cytotoxicity assay of NCTD in CT26 colorectal adenocarcinoma cells showed a dose- and time-dependent decrease in cell viability.
  • [MeSH-major] Adenocarcinoma / enzymology. Bicyclo Compounds, Heterocyclic / pharmacology. Colorectal Neoplasms / enzymology. Lung Neoplasms / prevention & control. Matrix Metalloproteinase Inhibitors
  • [MeSH-minor] Animals. Cell Adhesion / drug effects. Male. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Mice. Mice, Inbred BALB C. Neoplasm Metastasis / prevention & control. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15711181.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bicyclo Compounds, Heterocyclic; 0 / Matrix Metalloproteinase Inhibitors; 5442-12-6 / norcantharidin; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


64. Greulich H: The genomics of lung adenocarcinoma: opportunities for targeted therapies. Genes Cancer; 2010 Dec;1(12):1200-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The genomics of lung adenocarcinoma: opportunities for targeted therapies.
  • Lung adenocarcinoma is one such cancer, responsible for approximately half of lung cancer deaths each year.
  • Development of targeted therapies is thought to hold the most promise for successfully treating this disease, but a targeted approach is dependent on understanding the genomic state of the tumor cells.
  • Exon-directed sequencing of large numbers of lung adenocarcinoma tumor samples has provided an initial low-resolution image of the somatic mutation profile of these tumors.
  • Such cancer sequencing studies have confirmed the high frequency of TP53 and KRAS mutations in lung adenocarcinoma, have found inactivating mutations in known tumor suppressor genes not previously associated with lung adenocarcinoma, and have identified oncogenic mutations of EGFR upon which the first targeted therapy for lung adenocarcinoma patients was based.
  • It is anticipated that upcoming whole-exome and whole-genome lung adenocarcinoma sequencing experiments will reveal a more detailed landscape of somatic mutations that can be exploited for therapeutic purposes.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2006 Jul;10(1):25-38 [16843263.001]
  • [Cites] Cell. 1990 Jul 13;62(1):187-92 [1694727.001]
  • [Cites] PLoS Med. 2006 Dec;3(12):e485 [17177598.001]
  • [Cites] Curr Opin Genet Dev. 2007 Feb;17(1):45-51 [17208432.001]
  • [Cites] Curr Opin Genet Dev. 2007 Feb;17(1):23-30 [17227708.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):561-70 [17290066.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):5023-7 [17311002.001]
  • [Cites] Curr Opin Neurol. 2007 Apr;20(2):135-41 [17351482.001]
  • [Cites] Science. 2007 May 18;316(5827):1039-43 [17463250.001]
  • [Cites] PLoS One. 2007;2(5):e426 [17487277.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4665-70 [17510392.001]
  • [Cites] Nature. 2007 Jul 26;448(7152):439-44 [17611497.001]
  • [Cites] Cancer Cell. 2007 Jul;12(1):81-93 [17613438.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):561-6 [17625570.001]
  • [Cites] Oncol Rep. 2007 Sep;18(3):623-8 [17671710.001]
  • [Cites] Nature. 2007 Aug 16;448(7155):807-10 [17676035.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):893-8 [17982442.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7 [18093943.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2070-5 [18227510.001]
  • [Cites] Cell Cycle. 2008 Mar 1;7(5):665-9 [18256540.001]
  • [Cites] Oncogene. 2008 Aug 7;27(34):4702-11 [18408761.001]
  • [Cites] Mod Pathol. 2008 May;21 Suppl 2:S16-22 [18437168.001]
  • [Cites] Cancer Res. 2010 Jul 1;70(13):5518-27 [20551065.001]
  • [Cites] N Engl J Med. 2010 Jun 24;362(25):2380-8 [20573926.001]
  • [Cites] Cancer Cell. 2010 Jul 13;18(1):63-73 [20609353.001]
  • [Cites] CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300 [20610543.001]
  • [Cites] Cancer Res. 2010 Sep 15;70(18):7253-63 [20823162.001]
  • [Cites] Nature. 2010 Sep 30;467(7315):596-9 [20823850.001]
  • [Cites] Cancer Res. 2010 Dec 1;70(23):9827-36 [20952506.001]
  • [Cites] Nat Rev Cancer. 2010 Nov;10(11):760-74 [20966921.001]
  • [Cites] N Engl J Med. 2010 Oct 28;363(18):1693-703 [20979469.001]
  • [Cites] N Engl J Med. 2010 Oct 28;363(18):1734-9 [20979473.001]
  • [Cites] Cancer Res. 2010 Dec 15;70(24):10038-43 [21030459.001]
  • [Cites] Trends Mol Med. 2011 Feb;17(2):88-96 [21087899.001]
  • [Cites] Cell. 1990 Jul 13;62(1):193-201 [2114220.001]
  • [Cites] Cancer Res. 2011 Jan 1;71(1):197-205 [21199802.001]
  • [Cites] Cancer Res. 2011 Feb 1;71(3):1081-91 [21266357.001]
  • [Cites] Science. 1990 Jul 13;249(4965):181-6 [2134734.001]
  • [Cites] Science. 1988 Jul 15;241(4863):353-7 [2838909.001]
  • [Cites] Annu Rev Biochem. 1987;56:779-827 [3304147.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3 [5279523.001]
  • [Cites] Nat Med. 1995 Jul;1(7):686-92 [7585152.001]
  • [Cites] Cancer Res. 1995 Feb 1;55(3):505-9 [7834618.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):191-202 [8000996.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3346-51 [10416591.001]
  • [Cites] Oncogene. 1999 Oct 21;18(43):5843-9 [10557071.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Mar;30(3):316-21 [11170292.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1038-42 [11287973.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] Science. 2001 Aug 3;293(5531):876-80 [11423618.001]
  • [Cites] J Clin Pathol. 2001 Jul;54(7):512-6 [11429421.001]
  • [Cites] Genes Dev. 2001 Sep 1;15(17):2177-96 [11544175.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):55-67 [11900252.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3659-62 [12097271.001]
  • [Cites] Oncogene. 2003 Sep 11;22(39):7905-12 [12970738.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3231-3 [1317264.001]
  • [Cites] Cancer Res. 1992 Dec 1;52(23):6696-8 [1423316.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):91-102 [14749129.001]
  • [Cites] Science. 2004 Apr 23;304(5670):554 [15016963.001]
  • [Cites] Cell. 2004 Mar 19;116(6):855-67 [15035987.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Nature. 1992 Sep 17;359(6392):235-7 [1528264.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] Nature. 2004 Sep 30;431(7008):525-6 [15457249.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4456-62 [15483017.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8816-20 [15604238.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8919-23 [15604253.001]
  • [Cites] Oncogene. 2005 Feb 17;24(8):1477-80 [15608678.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8195-203 [15623594.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):802-7 [15647370.001]
  • [Cites] Cancer Cell. 2005 Feb;7(2):179-91 [15710330.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):786-92 [15728811.001]
  • [Cites] PLoS Med. 2005 Mar;2(3):e73 [15737014.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 [15741570.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1642-6 [15753357.001]
  • [Cites] J Hum Genet. 2005;50(4):192-202 [15834506.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] Cancer Cell. 2005 Jun;7(6):561-73 [15950905.001]
  • [Cites] J Biol Chem. 2005 Sep 2;280(35):30984-93 [15987685.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):689-98 [16110319.001]
  • [Cites] Hum Gene Ther. 2005 Sep;16(9):1016-27 [16149900.001]
  • [Cites] PLoS Med. 2005 Nov;2(11):e313 [16187797.001]
  • [Cites] Nat Genet. 2005 Dec;37(12):1315-6 [16258541.001]
  • [Cites] Cell. 1991 Aug 9;66(3):589-600 [1651174.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6487-91 [16818618.001]
  • [Cites] Oncogene. 1998 Sep 17;17(11 Reviews):1395-413 [9779987.001]
  • [Cites] Clin Cancer Res. 1995 Jul;1(7):687-90 [9816033.001]
  • [Cites] Cancer Cell. 2002 Dec;2(6):463-72 [12498715.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5656-68 [14522880.001]
  • [Cites] Radiat Oncol. 2006;1:35 [16956411.001]
  • [Cites] Sci Signal. 2008;1(24):pe29 [18560018.001]
  • [Cites] J Thorac Oncol. 2010 Oct;5(10):1630-6 [20802351.001]
  • [Cites] J Clin Oncol. 2010 Oct 20;28(30):4616-20 [20855837.001]
  • [Cites] Nature. 1989 Dec 7;342(6250):705-8 [2531845.001]
  • [Cites] Science. 1989 Oct 27;246(4929):491-4 [2554494.001]
  • [Cites] Oncogene. 1988 Oct;3(4):471-5 [2856251.001]
  • [Cites] Cancer Res. 1988 Oct 15;48(20):5738-41 [3048648.001]
  • [Cites] Science. 1995 Jun 23;268(5218):1749-53 [7792600.001]
  • [Cites] Cancer Res. 1995 Dec 15;55(24):6200-9 [8521414.001]
  • [Cites] Cancer Res. 2008 Sep 15;68(18):7466-74 [18794134.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Oct;9(10):759-69 [18813293.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):967-70 [18923523.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):971-4 [18923524.001]
  • [Cites] Trends Biochem Sci. 1997 Jan;22(1):14-7 [9020586.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] J Biol Chem. 1997 May 30;272(22):14459-64 [9162087.001]
  • [Cites] Nature. 1998 Jan 8;391(6663):184-7 [9428765.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4275-83 [18594010.001]
  • [Cites] Cancer Res. 2008 Jul 15;68(14):5524-8 [18632602.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14(15):4877-82 [18676761.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):930-5 [18724359.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):6913-21 [18757405.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):975-8 [18923525.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1069-75 [18948947.001]
  • [Cites] Cancer Res. 2008 Nov 15;68(22):9375-83 [19010912.001]
  • [Cites] Nat Med. 2008 Dec;14(12):1351-6 [19029981.001]
  • [Cites] Nat Rev Drug Discov. 2008 Dec;7(12):979-87 [19043449.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):474-9 [19122144.001]
  • [Cites] PLoS One. 2009;4(2):e4576 [19238210.001]
  • [Cites] Cancer Cell. 2009 May 5;15(5):376-88 [19411067.001]
  • [Cites] Cancer Cell. 2009 Jun 2;15(6):489-500 [19477428.001]
  • [Cites] Cell. 2009 May 29;137(5):821-34 [19490892.001]
  • [Cites] Cell. 2009 May 29;137(5):835-48 [19490893.001]
  • [Cites] Nat Rev Cancer. 2009 Jul;9(7):463-75 [19536107.001]
  • [Cites] Nat Rev Cancer. 2009 Aug;9(8):563-75 [19629071.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4274-80 [19652055.001]
  • [Cites] N Engl J Med. 2009 Sep 3;361(10):947-57 [19692680.001]
  • [Cites] Nat Rev Cancer. 2009 Oct;9(10):701-13 [19693097.001]
  • [Cites] Nat Rev Cancer. 2009 Oct;9(10):749-58 [19776744.001]
  • [Cites] Oncogene. 2010 Jan 7;29(1):150-5 [19802009.001]
  • [Cites] Nature. 2009 Nov 5;462(7269):104-7 [19847165.001]
  • [Cites] Nature. 2009 Nov 5;462(7269):108-12 [19847166.001]
  • [Cites] Nat Rev Cancer. 2009 Nov;9(11):785-97 [19851314.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1085-9 [1996309.001]
  • [Cites] Nat Genet. 2010 Jan;42(1):83-8 [19966802.001]
  • [Cites] Lancet Oncol. 2010 Feb;11(2):121-8 [20022809.001]
  • [Cites] Nature. 2009 Dec 24;462(7276):1070-4 [20033049.001]
  • [Cites] J Biol Chem. 2010 Apr 2;285(14):10198-212 [20124408.001]
  • [Cites] Cancer Cell. 2010 Jan 19;17(1):77-88 [20129249.001]
  • [Cites] Nature. 2010 Mar 18;464(7287):431-5 [20130576.001]
  • [Cites] Cell. 2010 Jan 22;140(2):209-21 [20141835.001]
  • [Cites] Nature. 2010 Feb 18;463(7283):899-905 [20164920.001]
  • [Cites] Nature. 2010 Mar 18;464(7287):427-30 [20179705.001]
  • [Cites] Biochem Pharmacol. 2010 Sep 1;80(5):666-73 [20211150.001]
  • [Cites] Clin Cancer Res. 2010 Apr 15;16(8):2450-7 [20332327.001]
  • [Cites] Nature. 2010 May 27;465(7297):473-7 [20505728.001]
  • [Cites] Sci Signal. 2010;3(124):ra44 [20516478.001]
  • [Cites] Cancer Cell. 2010 Jun 15;17(6):547-59 [20541700.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Aug 15;202(3):1426-30 [8060323.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6997-7000 [12460918.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7001-3 [12460919.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):24108-12 [12700230.001]
  • [Cites] Nat Genet. 2003 Jun;34(2):148-50 [12717436.001]
  • [Cites] Nat Genet. 1998 Apr;18(4):360-4 [9537419.001]
  • [Cites] Trends Biochem Sci. 1998 Aug;23(8):291-6 [9757829.001]
  • (PMID = 21779443.001).
  • [ISSN] 1947-6027
  • [Journal-full-title] Genes & cancer
  • [ISO-abbreviation] Genes Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3092285
  • [Keywords] NOTNLM ; EGFR / cancer sequencing / lung adenocarcinoma / targeted therapy
  •  go-up   go-down


65. Abascal Junquera JM, Cecchini Rosell L, Martos Calvo R, Salvador Lacambra C, Celma Doménech A, De Torres I, Morote Robles J: [Presentation of a new case of primary clear cell adenocarcinoma of the urethra and its surgical management]. Actas Urol Esp; 2007 Apr;31(4):411-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Presentation of a new case of primary clear cell adenocarcinoma of the urethra and its surgical management].
  • [Transliterated title] Presentación de un nuevo caso de adenocarcinoma de células claras uretral y su manejo quirúrgico.
  • OBJECTIVE: To present a new case of a primary clear cell adenocarcinoma of the urethra and its surgical management.
  • MATERIAL AND METHODS: We describe the clinical, diagnosis, treatment and development of this kind of tumor.
  • [MeSH-major] Adenocarcinoma, Clear Cell / surgery. Urethral Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633929.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 11
  •  go-up   go-down


66. Saghravanian N, Mohtasham N, Jafarzadeh H: Comparison of immunohistochemical markers between adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma. J Oral Sci; 2009 Dec;51(4):509-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of immunohistochemical markers between adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma.
  • Adenoid cystic carcinoma (AdCC) and polymorphous low-grade adenocarcinoma (PLGA) have several common histological and clinicopathological features that may create diagnostic difficulties.
  • Thus, immunohistochemistry can be helpful for differential diagnosis of AdCC and PLGA, particularly that for CEA, vimentin, and Ki-67.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor. Carcinoma, Adenoid Cystic / chemistry. Salivary Gland Neoplasms / chemistry
  • [MeSH-minor] Carcinoembryonic Antigen / analysis. Diagnosis, Differential. Humans. Immunoenzyme Techniques. Ki-67 Antigen / analysis. Vimentin / analysis


67. Lustosa SA, Logullo A, Artigiani R, Saad SS, Goldenberg A, Matos D: Analysis of the correlation between p53 and bcl-2 expression with staging and prognosis of the colorectal adenocarcinoma. Acta Cir Bras; 2005 Sep-Oct;20(5):353-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the correlation between p53 and bcl-2 expression with staging and prognosis of the colorectal adenocarcinoma.
  • PURPOSE: To analyze the correlation between p53 and bcl-2 expression and colorectal adenocarcinoma staging and prognosis.
  • METHODS: This was a retrospective series of 125 colorectal adenocarcinoma patients (67 women and 58 men; ages 30-87 years) who underwent surgery with curative intent.
  • CONCLUSION: No correlation was found between tumor expression of p53 and bcl-2 and the TNM staging, recurrence, survival and cancer-related mortality in colorectal adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16186958.001).
  • [ISSN] 0102-8650
  • [Journal-full-title] Acta cirurgica brasileira
  • [ISO-abbreviation] Acta Cir Bras
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


68. Reichelt U, Duesedau P, Tsourlakis MCh, Quaas A, Link BC, Schurr PG, Kaifi JT, Gros SJ, Yekebas EF, Marx A, Simon R, Izbicki JR, Sauter G: Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol; 2007 Jan;20(1):120-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus.
  • A tissue microarray was constructed from 255 primary esophageal cancers (110 adenocarcinomas and 145 squamous cell carcinomas), 89 nodal and 33 distant metastases.
  • Amplification was seen in 16/110 (15%) adenocarcinomas and in 7/145 (5%) squamous cell carcinomas.
  • There was a strong association between HER-2 amplification and overexpression, especially in adenocarcinomas (P<0.0001, log rank).
  • We conclude that esophageal adenocarcinomas belong to those cancer types with relevant frequency high-level HER-2 gene amplification clinical trials or individual case studies investigating the response of metastatic HER-2-positive esophageal cancers to Herceptin((R)) should be undertaken.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Esophageal Neoplasms / pathology. Gene Amplification. Gene Expression Regulation, Neoplastic. Genes, erbB-2. Receptor, ErbB-2 / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Male. Matched-Pair Analysis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Time Factors. Tissue Array Analysis. Up-Regulation

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143264.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


69. Muldrew KL, Edberg SC: Growth of adenocarcinoma on routine microbiological media inoculated with fluid from a pleural effusion in an 82-year-old female. J Clin Microbiol; 2009 Apr;47(4):1255-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth of adenocarcinoma on routine microbiological media inoculated with fluid from a pleural effusion in an 82-year-old female.
  • We report the first documented case of adenocarcinoma cell growth on routine microbiological media.
  • [MeSH-major] Adenocarcinoma. Culture Media / chemistry. Pleural Effusion / metabolism. Tissue Culture Techniques / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Appl Microbiol. 2008 Apr;104(4):1228-37 [18028360.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6035-8 [12414625.001]
  • [Cites] J Clin Microbiol. 2003 Apr;41(4):1447-53 [12682128.001]
  • [Cites] J Microbiol Methods. 2003 Dec;55(3):541-55 [14607398.001]
  • [Cites] Cancer Res. 1983 Nov;43(11):5321-7 [6352018.001]
  • [Cites] J Clin Microbiol. 2007 Mar;45(3):1058-62 [17251404.001]
  • [Cites] Pathobiology. 1993;61(1):31-5 [8216820.001]
  • [Cites] J Clin Microbiol. 2005 Jul;43(7):3431-4 [16000470.001]
  • [Cites] J Mol Diagn. 2005 Nov;7(5):641-5 [16258164.001]
  • [Cites] Intensive Care Med. 2007 Jan;33(1):143-7 [17091241.001]
  • [Cites] Int J Cancer. 1988 Feb 15;41(2):227-30 [3338872.001]
  • (PMID = 19144796.001).
  • [ISSN] 1098-660X
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media
  • [Other-IDs] NLM/ PMC2668316
  •  go-up   go-down


70. Piana S, Asioli S, Foroni M: Oncocytic adenocarcinoma of the rectum arising on a villous adenoma with oncocytic features. Virchows Arch; 2006 Feb;448(2):228-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic adenocarcinoma of the rectum arising on a villous adenoma with oncocytic features.
  • Rectal adenocarcinoma with diffuse oncocytic features is a very rare lesion, having been reported only once in the English literature.
  • We describe a case of oncocytic adenocarcinoma of the rectum, associated with a villous adenoma, arising on a 66-year-old man.
  • On histological examination, the adenocarcinoma was composed of neoplastic glands lined by a strongly eosinophilic, granular epithelium that deeply infiltrated the rectal wall.
  • Superficially, a villous adenoma with high-grade dysplasia was evident; adenomatous cells showed focal eosinophilic changes, consisting of a large granular cytoplasm, an oval atypical nucleus, and a prominent nucleolus.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Villous / pathology. Rectal Neoplasms / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Aug;30(8):926-33 [10452505.001]
  • [Cites] Cell. 1993 Aug 27;74(4):597-608 [8358789.001]
  • [Cites] Virchows Arch. 1998 Jul;433(1):5-12 [9692819.001]
  • [Cites] Semin Diagn Pathol. 1999 May;16(2):98-104 [10452575.001]
  • [Cites] Virchows Arch. 2000 Aug;437(2):107-15 [10993269.001]
  • [Cites] Virchows Arch. 2000 Jun;436(6):602-7 [10917176.001]
  • [Cites] Int J Surg Pathol. 2005 Jan;13(1):29-35 [15735852.001]
  • [Cites] Semin Diagn Pathol. 1999 May;16(2):82-90 [10452573.001]
  • [Cites] Pathol Oncol Res. 1999;5(4):273-9 [10607921.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1309-12 [9721092.001]
  • [Cites] J Clin Pathol. 1995 Jan;48(1):46-52 [7706518.001]
  • [Cites] Hum Pathol. 1996 Oct;27(10):1071-6 [8892593.001]
  • [Cites] Virchows Arch. 2003 Oct;443(4):579-82 [12955503.001]
  • [Cites] J Pathol. 1994 Apr;172(4):337-42 [8207614.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):458-65 [11914623.001]
  • [Cites] Am J Surg Pathol. 1994 Oct;18(10):1054-64 [7522412.001]
  • [Cites] Semin Diagn Pathol. 1999 May;16(2):146-61 [10452580.001]
  • [Cites] Hum Pathol. 1996 Feb;27(2):102-10 [8617450.001]
  • [Cites] Virchows Arch Pathol Anat Physiol Klin Med. 1962;335:452-83 [13904234.001]
  • [Cites] Semin Diagn Pathol. 1999 May;16(2):126-34 [10452578.001]
  • [Cites] Hum Pathol. 1989 Jul;20(7):696-700 [2661411.001]
  • [Cites] Virchows Arch. 1997 Aug;431(2):111-7 [9293892.001]
  • [Cites] Virchows Arch. 1997 Feb;430(2):125-30 [9083515.001]
  • [Cites] Semin Diagn Pathol. 1999 May;16(2):117-25 [10452577.001]
  • [Cites] J Pathol. 1993 Apr;169(4):431-7 [8501540.001]
  • [Cites] Semin Diagn Pathol. 1999 May;16(2):135-45 [10452579.001]
  • (PMID = 16450120.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CDX2 Transcription Factor; 0 / CDX2 protein, human; 0 / Carcinoembryonic Antigen; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


71. Manfredi S, Thiebot T, Henno S, Falize L, Bretagne JF, Meunier B: Complete response of an initially non-surgical adenocarcinoma of the duodenum to chemotherapy with the FOLFOX 4 regimen. J Gastrointest Surg; 2009 Dec;13(12):2309-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response of an initially non-surgical adenocarcinoma of the duodenum to chemotherapy with the FOLFOX 4 regimen.
  • INTRODUCTION: The incidence of adenocarcinoma of the small bowel is very low in comparison with that of colorectal cancer.
  • No standard chemotherapy is defined for non-surgical adenocarcinoma of the small bowel.
  • CASE REPORT: We report here the case of a young patient with an initially non-surgical adenocarcinoma of the duodenum treated in a palliative setting with the FOLFOX 4 chemotherapy regimen.
  • CONCLUSION: The FOLFOX 4 regimen seems to be efficacious for some small-bowel adenocarcinomas and can be expected to lead to downstaging.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Duodenal Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] ANZ J Surg. 2001 Jul;71(7):428-37 [11450920.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1 [10200775.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] J Gastrointest Surg. 2003 Nov;7(7):925-30 [14592670.001]
  • [Cites] Am J Surg. 1984 Jan;147(1):66-71 [6691554.001]
  • [Cites] J Clin Gastroenterol. 2001 Oct;33(4):267-82 [11588539.001]
  • [Cites] Am J Gastroenterol. 1994 May;89(5):699-701 [8172140.001]
  • [Cites] Oncology (Williston Park). 1997 Apr;11(4):529-36; discussion 545, 549-50 [9130275.001]
  • [Cites] Am J Surg. 1975 Dec;130(6):749-55 [1242874.001]
  • [Cites] Ann Surg Oncol. 1994 May;1(3):183-8 [7842287.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1296-300 [17031398.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2004 Jan;14(1):139-48 [15062387.001]
  • [Cites] Arch Surg. 2002 May;137(5):564-70; discussion 570-1 [11982470.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1716-23 [8253348.001]
  • [Cites] Gastroenterology. 1994 Dec;107(6):1675-9 [7958678.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Feb;5(2):81-4 [8850266.001]
  • [Cites] Dig Dis Sci. 1992 Aug;37(8):1179-84 [1499440.001]
  • [Cites] Ann Surg Oncol. 1994 Jan;1(1):73-8 [7834432.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]
  • [Cites] Am J Gastroenterol. 2006 Dec;101(12):2826-32 [17026561.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Mar;7(3):243-51 [9521441.001]
  • [Cites] Int J Epidemiol. 1996 Aug;25(4):722-8 [8921448.001]
  • [Cites] J Am Coll Surg. 1996 Aug;183(2):89-96 [8696551.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 5:v61-118 [14684501.001]
  • (PMID = 19585173.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


72. Chen YP, Yang JS, Liu DT, Yang WP: Long-term effects of proglumide on resection of cardiac adenocarcinoma. World J Gastroenterol; 2005 May 7;11(17):2549-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term effects of proglumide on resection of cardiac adenocarcinoma.
  • AIM: Patients with advanced stage cardiac adenocarcinoma have a very poor prognosis.
  • The aim of this study was to investigate the actions of proglumide as an adjuvant treatment to improve the postoperative long-term survival rate of patients with cardiac adenocarcinoma.
  • METHODS: We performed a randomized, controlled study of gastrin receptor antagonist proglumide in 301 patients with cardiac adenocarcinoma after proximal subtotal gastrectomy.
  • CONCLUSION: Proglumide is convenient to use with no obvious toxic side effects, and prolonged postoperative administration of proglumide as a postoperative adjuvant treatment can increase the survival rate of patients after resection of cardiac adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Anti-Ulcer Agents / administration & dosage. Heart Neoplasms / drug therapy. Proglumide / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15849809.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anti-Ulcer Agents; EPL8W5565D / Proglumide
  • [Other-IDs] NLM/ PMC4305741
  •  go-up   go-down


73. Hartmann A, Junker K, Dietmaier W, Schröder S, Lopez D, Hofstädter F, Blaszyk H: Molecular evidence for progression of nephrogenic metaplasia of the urinary bladder to clear cell adenocarcinoma. Hum Pathol; 2006 Jan;37(1):117-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular evidence for progression of nephrogenic metaplasia of the urinary bladder to clear cell adenocarcinoma.
  • Nephrogenic metaplasia or nephrogenic adenoma of the urinary tract may present a diagnostic challenge in surgical pathology practice.
  • Previous case reports suggest the possibility of nephrogenic metaplasia progressing to clear cell adenocarcinoma, but a malignant potential of nephrogenic metaplasia is generally not acknowledged.
  • A case of a 70-year-old female patient with multiple recurrences of nephrogenic metaplasia of the urinary bladder and subsequent development of clear cell adenocarcinoma is described.
  • Results of molecular studies, particularly comparative genomic hybridization analysis, suggest clonal evolution of nephrogenic metaplasia to clear cell adenocarcinoma in this case.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenoma / pathology. Precancerous Conditions / pathology. Urinary Bladder / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Clone Cells. Cystectomy. DNA, Neoplasm / analysis. Disease Progression. Disease-Free Survival. Female. Humans. Loss of Heterozygosity. Metaplasia / genetics. Metaplasia / metabolism. Metaplasia / pathology. Neoplasm Recurrence, Local. Nucleic Acid Hybridization. Urethra / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16360424.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


74. Wagner DG, Weisensel J, Mentrikoski MJ, Leo SD, Bonfiglio TA, Hoda RS: ThinPrep Pap test of endocervical adenocarcinoma with lymph node metastasis: report of a case in a 17-year-old woman. Diagn Cytopathol; 2010 Sep;38(9):633-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ThinPrep Pap test of endocervical adenocarcinoma with lymph node metastasis: report of a case in a 17-year-old woman.
  • Endocervical adenocarcinoma is an uncommon malignancy that is composed of multiple subtypes and accounts for approximately 15% of all cervical cancers.
  • In this article, we describe the cytomorphology and differential diagnosis of an AJCC clinical stage IIIb, FIGO IB2 endocervical adenocarcinoma in a 17-year-old woman in a ThinPrep Pap test.The patient was a 17-year-old G0P0 white woman with no significant past medical history and no prior history of cervical dysplasia.
  • A sample was sent to cytology that was interpreted as atypical endocervical cells, favor neoplasia.
  • A subsequent cervical biopsy was diagnosed as endocervical adenocarcinoma with villoglandular features and ultimately, a hysterectomy with lymph node dissection was performed.
  • The final diagnosis was endocervical adenocarcinoma with metastasis to three pelvic lymph nodes.The cytomorphology of endocervical adenocarcinoma on ThinPrep Pap test is similar to that described for conventionally-processed Pap smears.
  • This difficult diagnosis should be considered on a ThinPrep Pap test, regardless of age when the characteristic cytomorphology is observed.
  • On a cytology sample, it is advisable to state atypical endocervical cells, adenocarcinoma in situ, or endocervical adenocarcinoma without providing a specific subtype even if there is a predominance of features for a particular subtype.
  • [MeSH-major] Adenocarcinoma / diagnosis. Lymphatic Metastasis / diagnosis. Papanicolaou Test. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears / methods


75. Quadros CA, Lopes A, Araujo I, Fregnani JH, Fahel F: Upstaging benefits and accuracy of sentinel lymph node mapping in colorectal adenocarcinoma nodal staging. J Surg Oncol; 2008 Oct 1;98(5):324-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upstaging benefits and accuracy of sentinel lymph node mapping in colorectal adenocarcinoma nodal staging.
  • METHODS: Lymphatic mapping was performed using technetium-99m-phytate and patent blue in 52 consecutive colorectal adenocarcinoma patients.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Neoplasm Staging. Sentinel Lymph Node Biopsy / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18618578.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


76. Bjelovic M, Pesko P, Micev M, Todorovic V, Stojakov D, Sabljak P, Simic A, Ebrahimi K, Velickovic D, Spica B: The significance of lymphonodal micrometastasis in the patients with gastric adenocarcinoma. Acta Chir Iugosl; 2005;52(3):21-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of lymphonodal micrometastasis in the patients with gastric adenocarcinoma.
  • Micrometastasis is defined as microscopical deposit of malignant cells, less than 2mm in diameter, separated from the primary tumor.
  • The literature on micrometastases, with special resperct to nodal micrometastasis, and their implications in gastric adenocarcinoma have been reviewed.
  • It is more than obvious that there is no definite agreement neither about risk factors, nor definitive clinical significance of micrometastatic node involvement in the patients with gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16812989.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Serbia and Montenegro
  • [Number-of-references] 0
  •  go-up   go-down


77. Shicang Y, Guijun H, Guisheng Q, Yuying L, Guoming W, Ruiling G: Efficacy of chemotherapeutic agents under hypoxic conditions in pulmonary adenocarcinoma multidrug resistant cell line. J Chemother; 2007 Apr;19(2):203-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of chemotherapeutic agents under hypoxic conditions in pulmonary adenocarcinoma multidrug resistant cell line.
  • The aim of this study was to investigate the efficacy of seven cytotoxic drugs against the pulmonary adenocarcinoma multidrug-resistant cell line A549/MDR under hypoxia (3% O(2)), and to explore the possible mechanisms for the change of efficacy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Anoxia / physiopathology. Antineoplastic Agents / pharmacology. Drug Resistance, Multiple / drug effects. Drug Resistance, Neoplasm / drug effects. Lung Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17434831.001).
  • [ISSN] 1120-009X
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


78. Lee TK, Miller JS, Epstein JI: Rare histological patterns of prostatic ductal adenocarcinoma. Pathology; 2010 Jun;42(4):319-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare histological patterns of prostatic ductal adenocarcinoma.
  • AIMS: Prostatic ductal adenocarcinomas account for 1% of prostate cancers.
  • Most commonly, these lesions grow in large cribriform and/or papillary patterns or, as recently described, in a manner resembling prostatic intraepithelial neoplasia (i.e., 'PIN-like' prostatic ductal adenocarcinoma).
  • This study aims to report rare variants of ductal adenocarcinoma.
  • METHODS: Ten cases of rare patterns of prostatic ductal adenocarcinoma that have not been formally investigated prior to this study, primarily from one author's consultation service (1987-2009), were selected.
  • RESULTS: Two (n = 2) cases were prostatic ductal adenocarcinoma with mucinous and goblet cell features.
  • Three (n = 3) cases are the first described cases of foamy gland prostatic ductal adenocarcinoma.
  • Other unique cases were prostatic duct adenocarcinomas with associated Paneth cell-like neuroendocrine (n = 2), micropapillary (n = 2), and cystic papillary features (n = 1).
  • Four prostatic ductal adenocarcinomas had no evidence of disease at 2-8 years follow-up: foamy gland, Paneth cell-like, and micropapillary (two cases).
  • One mucinous prostatic ductal adenocarcinoma resulted in the patient's death and the other mucinous case was alive at 7 years and 2 months, yet with no information as to status of disease.
  • CONCLUSIONS: In summary, we report several rare and unique histological patterns of prostatic ductal adenocarcinoma.
  • These unusual cases also provide further support for the relationship between acinar and ductal adenocarcinoma.
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Humans. Male. Middle Aged. Paneth Cells / pathology. Prostatic Intraepithelial Neoplasia / pathology


79. Hosseini SY, Danesh AK, Parvin M, Basiri A, Javadzadeh T, Safarinejad MR, Nahabedian A: Incidental prostatic adenocarcinoma in patients with PSA less than 4 ng/mL undergoing radical cystoprostatectomy for bladder cancer in Iranian men. Int Braz J Urol; 2007 Mar-Apr;33(2):167-73; discussion 173-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental prostatic adenocarcinoma in patients with PSA less than 4 ng/mL undergoing radical cystoprostatectomy for bladder cancer in Iranian men.
  • OBJECTIVE: To assess the incidence of prostate adenocarcinoma in patients undergoing radical cystoprostatectomy due to bladder cancer in Iranian men.
  • MATERIALS AND METHODS: Fifty cystoprostatectomy specimens removed due to bladder malignancy (2004-2005) at two referral centers (Shaheed Modarress and Shaheed Labbafinejad Hospitals, Tehran, Iran) were examined for the coincidental finding of prostate cancer (PCa).
  • Pathologic grade, stage, morphometric volume, number of tumor foci and association with areas of high grade prostatic intraepithelial neoplasia (HGPIN) were assessed by light microscopy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Prostate-Specific Antigen / blood. Prostatic Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cystectomy. Humans. Incidental Findings. Iran. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Prostatectomy. Sensitivity and Specificity


80. Lotan TL, Epstein JI: Gleason grading of prostatic adenocarcinoma with glomeruloid features on needle biopsy. Hum Pathol; 2009 Apr;40(4):471-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gleason grading of prostatic adenocarcinoma with glomeruloid features on needle biopsy.
  • Glomerulations in prostatic adenocarcinoma are characterized by dilated glands containing intraluminal cribriform structures with a single point of attachment, resembling a renal glomerulus.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):125-8 [5948714.001]
  • [Cites] Hum Pathol. 1998 May;29(5):543-6 [9596281.001]
  • [Cites] Mod Pathol. 1998 Jun;11(6):543-51 [9647592.001]
  • [Cites] Am J Surg Pathol. 2008 Oct;32(10):1532-9 [18724248.001]
  • [Cites] Adv Anat Pathol. 2006 Jan;13(1):57-9 [16462155.001]
  • [Cites] Hum Pathol. 2006 Mar;37(3):292-7 [16613324.001]
  • [Cites] J Clin Pathol. 2007 Jan;60(1):35-42 [17213347.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):918-24 [10435561.001]
  • (PMID = 19128819.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA058236
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS403689; NLM/ PMC3484379
  •  go-up   go-down


81. Nissan A, Stojadinovic A, Shia J, Hoos A, Guillem JG, Klimstra D, Cohen AM, Minsky BD, Paty PB, Wong WD: Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated by surgery alone. J Clin Oncol; 2006 Sep 1;24(25):4078-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated by surgery alone.
  • PATIENTS AND METHODS: One hundred patients with primary T2-3, N0 adenocarcinoma of the rectum, uniformly treated by surgery alone, were studied.
  • The study end points were disease-free survival, disease-specific survival (DSS), time to pelvic recurrence (PR), and distant recurrence.
  • During this time period 30 patients (31.9%) died as a result of disease and 64 patients (68.1%) remained alive and disease free.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Neoplasm Recurrence, Local / diagnosis. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoembryonic Antigen / blood. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Prospective Studies. Risk Assessment. Risk Factors. Survival Analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16943525.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


82. Kim J, Sun CL, Mailey B, Prendergast C, Artinyan A, Bhatia S, Pigazzi A, Ellenhorn JD: Race and ethnicity correlate with survival in patients with gastric adenocarcinoma. Ann Oncol; 2010 Jan;21(1):152-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Race and ethnicity correlate with survival in patients with gastric adenocarcinoma.
  • PATIENTS AND METHODS: Patients with gastric adenocarcinoma treated in Los Angeles County from 1988 to 2006 were identified from the Los Angeles County Cancer Surveillance Program.
  • CONCLUSIONS: Asians with gastric adenocarcinoma have superior outcomes in Los Angeles County.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19622590.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


83. Jackson AS, Sohaib SA, Staffurth JN, Huddart RA, Parker CC, Horwich A, Dearnaley DP: Distribution of lymph nodes in men with prostatic adenocarcinoma and lymphadenopathy at presentation: a retrospective radiological review and implications for prostate and pelvis radiotherapy. Clin Oncol (R Coll Radiol); 2006 Mar;18(2):109-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of lymph nodes in men with prostatic adenocarcinoma and lymphadenopathy at presentation: a retrospective radiological review and implications for prostate and pelvis radiotherapy.
  • AIMS: To describe the distribution of enlarged lymph nodes by nodal group found radiologically in patients presenting with adenocarcinoma of the prostate.
  • This will help to define which nodal groups should be treated during the pelvic radiotherapy of patients with less advanced disease.
  • [MeSH-major] Adenocarcinoma / pathology. Lymphatic Irradiation. Lymphatic Metastasis / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16523810.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501019
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


84. Zhang YF, Qi HW, Zhao F, Li ZF, Guo L, Mu DG, Xu XX: [Effect of IL-4 on ABCG2 expression in human lung adenocarcinoma cell lines]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Sep;23(9):810-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of IL-4 on ABCG2 expression in human lung adenocarcinoma cell lines].
  • [MeSH-major] ATP-Binding Cassette Transporters / genetics. ATP-Binding Cassette Transporters / metabolism. Gene Expression Regulation, Neoplastic / drug effects. Interleukin-4 / pharmacology. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism
  • [MeSH-minor] ATP Binding Cassette Transporter, Sub-Family G, Member 2. Adenocarcinoma / genetics. Adenocarcinoma / pathology. Animals. Cell Line, Tumor. Dose-Response Relationship, Drug. Humans. Lung Neoplasms / genetics. Lung Neoplasms / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17825224.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 207137-56-2 / Interleukin-4
  •  go-up   go-down


86. Shimada K, Sakamoto Y, Nara S, Esaki M, Kosuge T, Hiraoka N: Analysis of 5-year survivors after a macroscopic curative pancreatectomy for invasive ductal adenocarcinoma. World J Surg; 2010 Aug;34(8):1908-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of 5-year survivors after a macroscopic curative pancreatectomy for invasive ductal adenocarcinoma.
  • BACKGROUND: Surgical resections for invasive ductal adenocarcinoma of the pancreas can provide the only chance of cure, although the 5-year survivors are not always equated with cure.
  • METHODS: A total of 229 who underwent a macroscopic curative pancreatectomy for invasive ductal adenocarcinoma between 1990 and 2003 and have been observed for more than 5 years from the time of resection were retrospectively analyzed.
  • Thirty patients (75%) were alive without recurrence, and eight (20%) died of disease within 7.3 years.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Proportional Hazards Models. Retrospective Studies. Risk Factors. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] Surgery. 2006 Nov;140(5):764-72 [17084719.001]
  • [Cites] Pancreas. 2004 Jan;28(1):103-4 [14707739.001]
  • [Cites] Cancer. 2009 Sep 15;115(18):4080-9 [19626671.001]
  • [Cites] Pancreas. 2004 Apr;28(3):219-30 [15084961.001]
  • [Cites] Ann Surg Oncol. 2008 May;15(5):1399-406 [18320285.001]
  • [Cites] Hepatogastroenterology. 2004 Mar-Apr;51(56):603-5 [15086214.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Pancreas. 2008 Nov;37(4):352-7 [18665012.001]
  • [Cites] Pancreas. 2004 Apr;28(3):235-40 [15084963.001]
  • [Cites] Gastroenterology. 2009 Jan;136(1):177-186.e1 [18992743.001]
  • [Cites] Surg Today. 1999;29(1):16-22 [9934826.001]
  • [Cites] Am J Clin Oncol. 2008 Dec;31(6):545-52 [19060585.001]
  • [Cites] Ann Surg. 2008 Mar;247(3):456-62 [18376190.001]
  • [Cites] Ann Surg Oncol. 2009 Apr;16(4):836-47 [19194760.001]
  • [Cites] Ann Surg. 1996 Mar;223(3):273-9 [8604907.001]
  • [Cites] J Am Coll Surg. 2004 May;198(5):722-31 [15110805.001]
  • [Cites] Cancer. 2007 Dec 1;110(11):2484-92 [17941009.001]
  • [Cites] Ann Surg. 1988 Aug;208(2):215-20 [2840866.001]
  • [Cites] J Gastrointest Surg. 2008 Apr;12(4):701-6 [18027062.001]
  • [Cites] Pancreas. 2006 Apr;32(3):271-5 [16628082.001]
  • [Cites] Virchows Arch. 1998 Sep;433(3):237-42 [9769127.001]
  • (PMID = 20376443.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


87. Odida M, Lloveras B, Guimera N, Weiderpass E: The usefulness of immunohistochemistry in tissue microarrays of Human Papillomavirus negative adenocarcinoma of the uterine cervix. BMC Res Notes; 2010;3:54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The usefulness of immunohistochemistry in tissue microarrays of Human Papillomavirus negative adenocarcinoma of the uterine cervix.
  • BACKGROUND: The origin of adenocarcinomas presenting on the cervix uteri may be doubtful, i.e. whether it is of cervical or endometrial origin, due to the overlapping morphological features.
  • We aimed to explore the use of immunohistochemistry profiles in tissue microarrays in archived samples of adenocarcinoma (ADC) of the cervix from Uganda that tested negative for HPV DNA.
  • By using immunohistochemistry in 13 HPV negative ADC, endocervical tumour origin was suspected in five CEA positive cases while two out of three vimentin positive samples were probably of endometrial origin, suggesting that CEA and vimentin may be valuable in distinguishing HPV negative cervical adenocarcinomas from endometrial adenocarcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2009 Jun;33(6):914-24 [19295407.001]
  • [Cites] Virchows Arch. 2001 Jul;439(1):55-61 [11499840.001]
  • [Cites] Pathology. 2007 Feb;39(1):97-111 [17365826.001]
  • [Cites] J Cutan Pathol. 2006 Sep;33(9):629-33 [16965338.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:286-92 [16515605.001]
  • [Cites] Mod Pathol. 2006 Aug;19(8):1091-100 [16648864.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):303-15 [16507827.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):347-53 [16445657.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1731-9 [9846964.001]
  • [Cites] Pathology. 2003 Oct;35(5):397-401 [14555383.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):3-13 [12807939.001]
  • [Cites] Virchows Arch. 2003 Mar;442(3):271-7 [12647218.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jul;21(3):217-23 [12068166.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):11-5 [11781517.001]
  • [Cites] Am J Surg Pathol. 2007 May;31(5):653-63 [17460447.001]
  • (PMID = 20199664.001).
  • [ISSN] 1756-0500
  • [Journal-full-title] BMC research notes
  • [ISO-abbreviation] BMC Res Notes
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2852389
  •  go-up   go-down


88. Si J, Fu X, Behar J, Wands J, Beer DG, Souza RF, Spechler SJ, Lambeth D, Cao W: NADPH oxidase NOX5-S mediates acid-induced cyclooxygenase-2 expression via activation of NF-kappaB in Barrett's esophageal adenocarcinoma cells. J Biol Chem; 2007 Jun 1;282(22):16244-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NADPH oxidase NOX5-S mediates acid-induced cyclooxygenase-2 expression via activation of NF-kappaB in Barrett's esophageal adenocarcinoma cells.
  • We have shown that the NADPH oxidase NOX5-S may play an important role in the progression from Barrett's esophagus to esophageal adenocarcinoma (EA) by increasing cell proliferation and decreasing apoptosis.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17403674.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R21 DK073327; United States / NCRR NIH HHS / RR / P20 RR17695; United States / NIDDK NIH HHS / DK / R21 DK073327-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / I-kappa B Proteins; 0 / Membrane Proteins; 0 / NF-kappa B p50 Subunit; 0 / Neoplasm Proteins; 0 / RNA, Small Interfering; 139874-52-5 / NF-kappaB inhibitor alpha; BBX060AN9V / Hydrogen Peroxide; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS1 protein, human; EC 1.14.99.1 / PTGS2 protein, human; EC 1.6.- / NOX5 protein, human; EC 1.6.3.1 / NADPH Oxidase; K7Q1JQR04M / Dinoprostone; SY7Q814VUP / Calcium
  •  go-up   go-down


89. Ramírez-Ramos A, Watanabe-Yamamoto J, Takano-Morón J, Gilman RH, Recavarren Arce S, Arias-Stella J, Yoshiwara-Wakabayashi E, Rodríguez-Ulloa C, Miyagui-Maeda J, Chinga-Alayo E, Mendoza-Requena D, Leey-Casella J, Rosas-Aguirre A, Velapatiño-Cochachi B, Guerra Valencia D: Decrease in prevalence of peptic ulcer and gastric adenocarcinoma at the Policlínico Peruano Japones, Lima, Peru, between the years 1985 and 2002. Analysis of 31,446 patients. Acta Gastroenterol Latinoam; 2006 Sep;36(3):139-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decrease in prevalence of peptic ulcer and gastric adenocarcinoma at the Policlínico Peruano Japones, Lima, Peru, between the years 1985 and 2002. Analysis of 31,446 patients.
  • AIM: To determine the prevalence of peptic ulcer and gastric adenocarcinoma in a population of middle and high socio-economic status in Lima, Peru, between 1985 and 2002.
  • MATERIAL AND METHODS: The prevalence of gastroduodenal ulcer and gastric adenocarcinoma was determined after studying by esophagogastroduodenoscopy 31,446 patients at the Policlínico Peruano Japonds (PPJ) between 1985 and 2002.
  • All patients had chronic upper gastrointestinal symptoms and had endoscopically proven diagnosis of active peptic ulcer or histological diagnosis of gastric adenocarcinoma.
  • Gastric adenocarcinoma prevalence also decreased from 3.19% in 1988 to 0.92% in 2002.
  • The prevalences of gastric ulcer (OR = 1.49, 95% IC 1.26-1.77, p < 0.001), duodenal ulcer (OR = 1.32, 95% IC 1.15-1.51, p < 0.001) and gastric adenocarcinoma (OR = 1.53, 95% IC 1.25-1.86, p < 0.001), decreased in the last eight years.
  • CONCLUSIONS: Over the study period, there was a significant decrease in the prevalence of peptic ulcer and gastric adenocarcinoma at the Policlinico Peruano Japonés, where patients from middle and high socio economic status are attended.
  • [MeSH-major] Adenocarcinoma / epidemiology. Peptic Ulcer / epidemiology. Stomach Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cross-Sectional Studies. Duodenal Ulcer / epidemiology. Endoscopy, Digestive System. Female. Humans. Male. Middle Aged. Peru / epidemiology. Prevalence. Sex Distribution. Social Class. Stomach Ulcer / diagnosis. Stomach Ulcer / epidemiology

  • MedlinePlus Health Information. consumer health - Peptic Ulcer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17407990.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Argentina
  •  go-up   go-down


90. Haupt B, Ro JY, Schwartz MR, Shen SS: Colorectal adenocarcinoma with micropapillary pattern and its association with lymph node metastasis. Mod Pathol; 2007 Jul;20(7):729-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal adenocarcinoma with micropapillary pattern and its association with lymph node metastasis.
  • This study explored the clinicopathological features of colorectal adenocarcinoma with a micropapillary carcinoma component and compared them with those of conventional colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Papillary / pathology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17464318.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Memon A, Ahmad Z, Qureshi A, Ahsan A, Barakzai A, Bhurgri Y: Staging of prostatic adenocarcinoma with radical prostatectomy specimens in Pakistan. Asian Pac J Cancer Prev; 2009 Oct-Dec;10(4):551-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging of prostatic adenocarcinoma with radical prostatectomy specimens in Pakistan.
  • OBJECTIVES: Data for pathological staging of radical prostatectomy specimens reported in the Section of Histopathology of a large tertiary care hospital in Pakistan were compared with sextant biopsy findings to determine whether clinically localized disease is actually localized pathologically.
  • Therefore, in the majority of cases, disease was not localized to the prostate and perineurial invasion was seen in all.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatectomy. Prostatic Neoplasms / pathology
  • [MeSH-minor] Humans. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Neoplasm Staging. Pakistan. Prognosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19827867.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


92. Yu EJ, Lee Y, Rha SY, Kim TS, Chung HC, Oh BK, Yang WI, Noh SH, Jeung HC: Angiogenic factor thymidine phosphorylase increases cancer cell invasion activity in patients with gastric adenocarcinoma. Mol Cancer Res; 2008 Oct;6(10):1554-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenic factor thymidine phosphorylase increases cancer cell invasion activity in patients with gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Angiogenesis Inducing Agents / metabolism. Stomach Neoplasms / enzymology. Stomach Neoplasms / pathology. Thymidine Phosphorylase / metabolism
  • [MeSH-minor] Actins / metabolism. Cell Adhesion / drug effects. Cell Line, Tumor. Cell Movement / drug effects. Collagen / metabolism. Deoxyribose / pharmacology. Drug Combinations. Drug Synergism. Enzyme Inhibitors / pharmacology. Humans. Laminin / metabolism. Neoplasm Invasiveness. Phosphatidylinositol 3-Kinases / metabolism. Protein Kinases / metabolism. Proteoglycans / metabolism. Recombinant Proteins / pharmacology. TOR Serine-Threonine Kinases

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18922971.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Angiogenesis Inducing Agents; 0 / Drug Combinations; 0 / Enzyme Inhibitors; 0 / Laminin; 0 / Proteoglycans; 0 / Recombinant Proteins; 119978-18-6 / matrigel; 533-67-5 / Deoxyribose; 9007-34-5 / Collagen; EC 2.4.2.4 / Thymidine Phosphorylase; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases
  •  go-up   go-down


93. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA: Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol; 2006 Jan 20;24(3):379-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
  • PATIENTS AND METHODS: Chemotherapy-naive patients with metastatic pancreatic adenocarcinoma were treated with a combination of gemcitabine 1,000 mg/m2 at 10 mg/m2/min together with cisplatin 20 mg/m2 on days 1 and 8 of a 21-day cycle.
  • Nine of 47 patients (19.1%) with measurable disease achieved a partial response, and 28 patients (59.6%) had disease stabilization for at least two treatment cycles.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. CA-19-9 Antigen / blood. Cisplatin / administration & dosage. Disease Progression. Disease-Free Survival. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Middle Aged. Research Design. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 Jan 20;24(3):327-9 [16344312.001]
  • (PMID = 16344320.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / CA-19-9 Antigen; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


94. Delpero JR, Turrini O: [Locally advanced pancreatic adenocarcinoma. Chemoradiotherapy, reevaluation and secondary resection]. Cancer Radiother; 2006 Nov;10(6-7):462-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Locally advanced pancreatic adenocarcinoma. Chemoradiotherapy, reevaluation and secondary resection].
  • PATIENTS AND METHODS: We report 18 resections among 29 locally advanced pancreatic cancers; 15 patients were treated with neoadjuvant 5-FU-cisplatin based (13) or taxotere based (2 patients) chemoradiotherapy (45 Gy), and 3 patients without histologically proven adenocarcinoma were resected without any preoperative treatment.
  • A mesenteric infarction was the cause of a late death at 3 years in a disease free patient (radiation induced injury of the superior mesenteric artery).
  • The best therapeutic strategy remains to be defined, because the majority of patients ultimately succumb with distant metastatic disease.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Length of Stay. Neoplasm Staging. Pancreatectomy / methods. Radiotherapy Dosage. Survival Analysis. Taxoids / therapeutic use

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16987678.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


95. Al-Amri AM: Long-Term Survival of Gastric Adenocarcinoma without Therapy: Case Report. Oman Med J; 2010 Oct;25(4):303-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-Term Survival of Gastric Adenocarcinoma without Therapy: Case Report.
  • Planning for treatment of gastric adenocarcinoma in a patient previously treated with partial gastrectomy for primary gastric lymphoma is difficult.
  • Long term survival of advanced gastric adenocarcinoma is poor with therapy and even worse without treatment.
  • The only potentially curative treatment for gastric adenocarcinoma is surgical resection with adequate margins.
  • This report presents a case of gastric adenocarcinoma in a patient who had primary gastric lymphoma treated with partial gastrectomy.
  • The patient is still alive 6 years after diagnosis with no signs of progression despite the fact that no active treatment was given.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22043363.001).
  • [ISSN] 2070-5204
  • [Journal-full-title] Oman medical journal
  • [ISO-abbreviation] Oman Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Oman
  • [Other-IDs] NLM/ PMC3191651
  •  go-up   go-down


96. Burjonrappa SC, Reddimasu S, Nawaz Z, Gao X, Sharma P, Loggie B: Mucin expression profile in Barrett's, dysplasia, adenocarcinoma sequence in the esophagus. Indian J Cancer; 2007 Jan-Mar;44(1):1-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucin expression profile in Barrett's, dysplasia, adenocarcinoma sequence in the esophagus.
  • BACKGROUND: The molecular events that accompany the progression to adenocarcinoma (ADC) of the esophagus are poorly understood.
  • MUC1 expression was upregulated (7/7) in progression to adenocarcinoma (P=0.008).
  • [MeSH-major] Adenocarcinoma / metabolism. Barrett Esophagus / metabolism. Esophageal Neoplasms / metabolism. Esophagus / metabolism. Mucins / metabolism. Precancerous Conditions / metabolism
  • [MeSH-minor] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Gene Expression Regulation, Neoplastic. Humans. Intestinal Neoplasms / metabolism. Intestinal Neoplasms / pathology. Metaplasia / metabolism. Metaplasia / pathology. Mucin 5AC. Mucin-1. Mucin-2. Mucin-6. Retrospective Studies

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17401217.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / MUC6 protein, human; 0 / Muc2 protein, mouse; 0 / Muc5ac protein, mouse; 0 / Muc6 protein, mouse; 0 / Mucin 5AC; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucin-6; 0 / Mucins
  •  go-up   go-down


97. Kontos CK, Papadopoulos IN, Fragoulis EG, Scorilas A: Quantitative expression analysis and prognostic significance of L-DOPA decarboxylase in colorectal adenocarcinoma. Br J Cancer; 2010 Apr 27;102(9):1384-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative expression analysis and prognostic significance of L-DOPA decarboxylase in colorectal adenocarcinoma.
  • The aim of this study was to investigate the mRNA expression levels of the DDC gene and to evaluate its clinical utility in tissues with colorectal adenocarcinoma.
  • METHODS: Total RNA was isolated from colorectal adenocarcinoma tissues of 95 patients.
  • Kaplan-Meier survival curves showed that patients with DDC-positive tumours have significantly longer disease-free survival (P=0.009) and overall survival (P=0.027).
  • In Cox regression analysis of the entire cohort of patients, negative DDC proved to be a significant predictor of reduced disease-free (P=0.021) and overall survival (P=0.047).
  • CONCLUSIONS: The results of the study suggest that DDC mRNA expression may be regarded as a novel potential tissue biomarker in colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. Dopa Decarboxylase / genetics. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Humans. Lymph Nodes / pathology. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Prognosis. RNA, Messenger / genetics. RNA, Neoplasm / genetics. RNA, Neoplasm / isolation & purification. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Survivors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood Cells Mol Dis. 2009 Jan-Feb;42(1):92-8 [19041269.001]
  • [Cites] Neurochem Res. 2009 Jun;34(6):1089-100 [19005753.001]
  • [Cites] Nat Rev Cancer. 2009 Jul;9(7):489-99 [19536109.001]
  • [Cites] Mol Cell Biochem. 1990 May 10;94(2):147-56 [2374548.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6068-74 [2168288.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2161-5 [2006153.001]
  • [Cites] Biochemistry. 1992 Mar 3;31(8):2229-38 [1540578.001]
  • [Cites] Br J Cancer. 1992 Jul;66(1):148-54 [1379057.001]
  • [Cites] J Natl Cancer Inst. 1992 Oct 21;84(20):1572-5 [1404450.001]
  • [Cites] Biochemistry. 1992 Nov 24;31(46):11546-50 [1445888.001]
  • [Cites] Lancet. 1992 Dec 5;340(8832):1369-73 [1360088.001]
  • [Cites] N Engl J Med. 1994 Jul 28;331(4):213-21 [8015568.001]
  • [Cites] Biochem Pharmacol. 1995 Sep 7;50(6):845-50 [7575647.001]
  • [Cites] J Neurochem. 1995 Dec;65(6):2409-16 [7595534.001]
  • [Cites] Neurochem Res. 1996 Sep;21(9):1075-87 [8897471.001]
  • [Cites] N Engl J Med. 1996 Dec 5;335(23):1727-32 [8929264.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):427-33 [9469325.001]
  • [Cites] Gastroenterology. 1998 Jun;114(6):1180-7 [9609754.001]
  • [Cites] Dis Colon Rectum. 1998 Jun;41(6):755-60 [9645744.001]
  • [Cites] Br J Cancer. 1999 Jan;79(2):191-203 [9888457.001]
  • [Cites] Clin Biochem. 2008 Oct;41(14-15):1140-9 [18586020.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] J Neuroimmunol. 2009 Nov 30;216(1-2):51-8 [19800137.001]
  • [Cites] Eur J Cancer. 2010 Mar;46(4):765-81 [20116997.001]
  • [Cites] Biochem Pharmacol. 1999 Jun 15;57(12):1341-4 [10353253.001]
  • [Cites] Am J Pathol. 1999 Jul;155(1):17-21 [10393831.001]
  • [Cites] Neurochem Res. 2004 Oct;29(10):1817-23 [15532536.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7252-9 [15534099.001]
  • [Cites] CA Cancer J Clin. 2004 Nov-Dec;54(6):295-308 [15537574.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):609-18 [15659508.001]
  • [Cites] Br J Cancer. 2005 Feb 14;92(3):434-44 [15668707.001]
  • [Cites] J Gastrointest Surg. 2005 Mar;9(3):336-42 [15749593.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2606-11 [15814640.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9901-6 [15998737.001]
  • [Cites] Neurochem Res. 2005 May;30(5):641-9 [16176068.001]
  • [Cites] Eur J Cancer. 2005 Sep;41(14):2060-70 [16125380.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7518-28 [16172461.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2005 Nov;372(3):228-35 [16247607.001]
  • [Cites] J Histochem Cytochem. 2006 Aug;54(8):863-75 [16517981.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5313-27 [17060676.001]
  • [Cites] Hum Pathol. 2007 Jan;38(1):161-70 [16997353.001]
  • [Cites] Mol Cancer. 2007;6:38 [17553164.001]
  • [Cites] Dig Dis Sci. 2008 May;53(5):1289-96 [17934851.001]
  • [Cites] Gut. 2008 Jul;57(7):941-50 [18364437.001]
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] Dig Surg. 2000;17(3):209-15 [10867451.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):162-8 [10900274.001]
  • [Cites] Clin Cancer Res. 2000 Nov;6(11):4365-72 [11106255.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):153-6 [11668491.001]
  • [Cites] Int J Cancer. 2002 Jan 1;97(1):72-81 [11774246.001]
  • [Cites] Methods. 2001 Dec;25(4):386-401 [11846608.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Br J Cancer. 2002 Sep 9;87(6):630-4 [12237773.001]
  • [Cites] Eur J Cancer. 2003 Apr;39(6):718-27 [12651195.001]
  • [Cites] Neurochem Res. 2003 Jun;28(6):797-803 [12718431.001]
  • [Cites] Biochem J. 2003 Oct 15;375(Pt 2):373-83 [12864730.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):529-36 [14752076.001]
  • [Cites] Br J Cancer. 2004 Feb 9;90(3):665-71 [14760382.001]
  • [Cites] Diagn Mol Pathol. 2004 Sep;13(3):135-43 [15322424.001]
  • [Cites] Proc Natl Acad Sci U S A. 1972 Feb;69(2):343-7 [4536745.001]
  • [Cites] Endocrinology. 1983 Apr;112(4):1524-9 [6339207.001]
  • [Cites] Biochemistry. 1983 Dec 20;22(26):6058-63 [6661425.001]
  • [Cites] Cancer. 1986 May 1;57(9):1866-70 [3485470.001]
  • [Cites] Cancer Res. 1988 Jul 15;48(14):4078-82 [3383200.001]
  • [Cites] Biochem Biophys Res Commun. 1989 Nov 15;164(3):1024-30 [2590185.001]
  • [CommentIn] Br J Cancer. 2010 Oct 26;103(9):1475-6 [20859286.001]
  • (PMID = 20424616.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 4.1.1.- / Dopa Decarboxylase
  • [Other-IDs] NLM/ PMC2865762
  •  go-up   go-down


98. Adán-Merino L, Gómez-Senent S, Froilán-Torres C, Suárez J, Martín- Arranz E, Larrauri J, Mora-Sanz P, Segura-Cabral JM, Aldeguer-Martinez M: [Gastric adenocarcinoma in young adults; comparative study with older patients]. Rev Gastroenterol Mex; 2010;75(3):253-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric adenocarcinoma in young adults; comparative study with older patients].
  • [Transliterated title] Adenocarcinoma gástrico en adultos jóvenes; estudio comparativo con pacientes mayores.
  • BACKGROUND: Gastric adenocarcinoma (GA) has been considered a disease of elderly age and has been rarely reported in patients younger than 35 years of age.
  • CONCLUSION: Gastric adenocarcinoma is rare in young patients and most cases presented at advanced clinical stage similar to elderly patients, so the prognosis in both age groups is poor.
  • For this reason is important to be aware of alarm symptoms and risk factors in order to perform an early endoscopic diagnosis and a treatment with curative intent.
  • [MeSH-major] Adenocarcinoma / epidemiology. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20959173.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


99. Rebai W, Fterich F, Makni A, Ksantini R, Bedioui H, Daghfous A, Chebbi F, Jouini M, Ammous A, Kacem M, Ben Safta Z: [Early gastric adenocarcinoma]. Tunis Med; 2010 Jan;88(1):1-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Early gastric adenocarcinoma].
  • [Transliterated title] Adénocarcinome superficiel de l'estomac.
  • AIM: the purpose of this study was to determine the epidemiological and clinical behaviour of the superficial adenocarcinoma of the stomach, to clarify its pathological characteristics, its therapy and prognosis.
  • METHODS: Over a period of 14 years (1990-2004), 16 patients were operated for a superficial gastric adenocarcinoma among 155 gastric cancers treated during the same period in the service of general surgery "A" La Rabta.
  • RESULTS: The superficial gastric adenocarcinoma represented 10.3% of our series.
  • Two patients were followed for a chronic stomach ulcer, a patient is followed for Biermer anaemia and another one for Menetrier disease.
  • CONCLUSION: the superficial gastric adenocarcinoma is rare.
  • The follow up of precancerous states allows its diagnosis.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Gastrectomy / methods. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Early Detection of Cancer. Female. Follow-Up Studies. Humans. Incidence. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Prognosis. Pyloric Antrum / pathology. Retrospective Studies. Survival Rate. Treatment Outcome. Tunisia / epidemiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20415204.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


100. Terada T: Non-invasive Adenocarcinoma of the Vermiform Appendix: Incidence and Report of Four Cases among 512 Appendectomies. Gastroenterology Res; 2009 Aug;2(4):238-241
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-invasive Adenocarcinoma of the Vermiform Appendix: Incidence and Report of Four Cases among 512 Appendectomies.
  • As the results, 4 cases (incidence: 0.8%) of non-invasive adenocarcinoma were found.
  • The age of the 4 patients with adenocarcinoma was 48, 39, 84 and 86 years, respectively.
  • Pathologically, all the 4 tumors were non-invasive adenocarcinomas: 2 cases were flat type adenocarcinoma, 1 case was papillary adenocarcinoma, and 1 case was mucinous adenocarcinoma.
  • The results suggest that incidence of appendiceal adenocarcinoma was 0.8% of all appendectomies, and that non-invasive adenocarcinoma of the appendix shows variable morphologies, and that postoperative clinical outcome of non-invasive appendiceal tumor is good.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27942282.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Adenocarcinoma / Appendix / Histopathology / Non-invasive carcinoma / appendicitis
  •  go-up   go-down






Advertisement